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Tuberculosis (TB) continues to pose a significant health risk to morbidity and mortality 
worldwide.  Mycobacterium tuberculosis, the causative agent of TB, is responsible for nearly 10 
million new cases of active disease and 2 million deaths annually.  While the majority of M. 
tuberculosis infected individuals are asymptomatic (termed latent TB) and contain the infection, 
a subset (~10%) of infected individuals either present initially with primary active disease or 
reactivate subsequently over the course of their lifetime.  The precise immune mechanisms 
responsible for this observed spectrum remain unclear but recent evidence suggests that early 
events in M. tuberculosis infection influence host outcome.  In this dissertation, we utilized 
established non-human primate (NHP) models of M. tuberculosis to examine the early 
immunologic, pathologic, and contextual responses following infection.  The primary aim of this 
thesis was to develop a novel genomic barcoding approach to add to our in vivo toolbox 
permitting single-bacterial tracing to probe early events in a variety of infection contexts.  Our 
work validated the use of these bacterial tags and provided a unique ability to quantitatively track 
individual founding bacilli and their descendants in infected macaques.  We found that the 
majority of bacteria are able to establish infection (i.e. a primary granuloma) but only a subset of 
bacteria contributes to productive dissemination.  In addition, our barcode strategy permitted 
reinfection studies in which primary and secondary infections are separately evaluated using 
library-specific identifiers.  Our initial observations suggest that an ongoing primary infection 
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substantially limits secondary granuloma establishment and bacterial growth.  By adapting our 
current NHP model of TB with new genomic barcoding tools, our work has provided insight into 
bacterial dissemination, reinfection, and host variability.  Finally, our most recent studies are 
looking into the earliest context of the lung by probing the lung microbiome and its interaction 
with M. tuberculosis.  Our latest observations suggest that the microbial lung landscape is highly 
variable across individuals, is distinct from the oral cavity, and undergoes significant alterations 
following infection. Overall, this body of work reiterates the importance of appreciating the 
influence that early infection and single lesion dynamics contributes to host outcome. 
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1.0  A BRIEF INTRODUCTION INTO MYCOBACTERIUM TUBERCULOSIS, TB 
BIOLOGY AND EARLY INFECTION 
Sections of the chapter are adapted from the original publication: 
Cadena AM, Flynn JL, & Fortune SM (2016) The Importance of First Impressions: Early Events 
in Mycobacterium tuberculosis Infection Influence Outcome. mBio 7(2):e00342-00316. 
& 
from the review in preparation: 
Cadena AM, Fortune SM, & Flynn JL  (2017) Heterogeinity in Tuberculosis: the Importance of 
Considering Local Conflicts in a Global Contex. 
1.1 THE BUG: ITS PERSISTENCE, SUCCESS, AND HOST INTERACTION 
1.1.1 Mycobacterium tuberculosis, an old threat remains 
Tuberculosis remains a global health threat.  In spite of an existing drug regimen and the M. 
bovis bacilli Calmette-Guerin (BCG) vaccine, there were 10.4 million incident cases of TB and 
1.8 million deaths in 20151.  The greatest global burden for active TB lies in sub-Saharan Africa, 
India, and China where effective TB control is hampered by co-infection, poverty, inadequate 
disease surveillance, questionable BCG vaccine efficacy, and increasing drug resistance1-4.  In 
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addition to these socio-economic barriers, our incomplete understanding of the human immune 
response further drives TB resurgence as a global infectious disease.  The lack of true immune 
correlates of protection to M. tuberculosis infection and disease5-7 coupled with the heterogeneity 
of the human immune response to TB8,9, impinge on the development of novel vaccines and anti-
mycobacterial drugs. 
1.1.2  Host outcome in TB, beyond the two-state paradigm 
Classically, Mycobacterium tuberculosis infection is thought to result in one of two states: latent 
infection or active disease. The former outcome is a clinically silent process defined by 
immunological containment and bacterial persistence and accounts for ninety percent of human 
infections with an estimated burden of approximately 2 billion individuals worldwide10,11.  By 
contrast, active disease is classified as a failed host response manifesting primarily as pulmonary 
TB typified by chronic cough, fever, sustained weight loss, wasting, and hemoptysis12.  In 2015, 
there were 10.4 million new cases of illness and 1.8 million deaths1 due to TB; this active disease 
state is estimated to occur in approximately 5% of initial infections in the first 18 months with a 
remaining risk of 5% over the course of one’s life13.  More recently, the TB field has embraced a 
newer paradigm that recognizes a spectrum of clinical outcomes within these two states7,14,15.  
The biological and immunological underpinning for this variability is not well understood and 
remains an open question in human TB. 
The large reservoir of asymptomatic latent infection in the human population represents a 
nuanced continuum of bacterial persistence and host containment ranging from cleared infection 
to low-grade tuberculosis14,15 (Figure 1).  This viewpoint extends the definition of subclinical, 
latent tuberculosis beyond a single status to better differentiate risk of reactivation, prioritize 
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preventive treatment, and emphasize host heterogeneity to M. tuberculosis infection.  Individuals 
that have sterilized infection would be least likely to reactivate and presumably last to require 
intervention.  By contrast, latently infected individuals who are harboring a low-grade, 
percolating infection would be at higher risk to reactivate and more likely to require treatment.  
In addition to better segregating individuals at higher risk of reactivation, this perspective 
provides greater appreciation for the dynamic nature of M. tuberculosis infection and the human 
immune response to TB, which, in turn, affords better explanation for those individuals who can 
control and clear infection as exhibited by persistent TST non-responders.  These individuals, 
despite documented high-risk exposure to TB, are consistently TST negative16-18 and suggest that 
intrinsic19 and innate immune factors might be contributing to mycobacterial clearance in the 
absence of an adaptive immune response20.  Lastly, this model reiterates the immunologic and 
pathologic variability underscoring all of these human outcomes, which is crucial to develop 
intervention strategies that recognize and target the unique, complex, and independent nature of 






Figure 1. Tuberculosis presents along a spectrum of host outcomes.  
Within the clinically-defined, binary classification of TB exists a more complex set of host outcomes to M. 
tuberculosis infection.  This spectrum is driven by multiple factors but is thought to reflect differences in M. 
tuberculosis burden, a balance of pro (P)- and anti (A)-inflammatory cytokines, and pathology.   
 
Evidence supporting this newer paradigm of human TB has been observed in human 
studies with 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography 
(FDG PET CT)21.  The authors find that among 35 ART-naïve, HIV-1 positive LTBI adults, 10 
patients with pulmonary irregularities indicative of subclinical disease had a significantly higher 
risk to present with active TB compared to the remaining 25 patients that had no subclinical 
pathology by FDG PET CT.  These findings mirror data in the macaque model of tuberculosis in 
which FDG PET CT features including elevated lung inflammation and extrapulmonary sites of 
infection predicted reactivation risk in latently infected macaques prior to tumor necrosis factor 
(TNF) neutralization with 92% sensitivity and specificity22.  Both of these studies validate the 
biological importance and subsequent clinical benefit in appreciating the variability of host 
outcomes in TB. 
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Clinical heterogeneity has also been observed in the context of recent studies examining 
blood transcriptional signatures related to host status. In 2010, Berry et al reported a 393-
transcript signature distinct for active TB in both intermediate and high burden areas relative to 
latent TB subjects and healthy controls23.  Interestingly, while the majority of latent individuals 
clustered independently, 10-25% of the LTBI subjects shared similar transcriptional profiles with 
active TB patients, and most likely highlighted individuals with subclinical, active disease.  
These shared transcriptional profiles observed in a subset of clinically-defined latent TB subjects 
reiterate the radiological findings above, and further emphasize the varied nature of this disease, 
which can even be distinguished in the periphery.  More recently, additional gene expression 
analysis of pulmonary and extra-pulmonary TB patients found that transcriptional profiles are 
influenced by symptom status and site of disease24.  Individuals with extra-pulmonary disease 
exhibited heterogeneous gene signatures in which the magnitude of response was related to the 
presence of symptoms and site; those individuals with the highest mean molecular distance to 
health had the highest percentage of patients within the group having one or more symptom of 
either fever, night sweats, chest pain, cough, or weight loss.  These findings suggest that illness 
is likely linked to the site of infection, bacterial burden, and site host response, which in turn 
contribute to the resulting diversity of transcriptional profile and ultimately host status.  In non-
human primates, similar transcriptional studies have interrogated both lung-specific granuloma 
changes25 as well as longitudinal changes in the blood26.  In the first study, granulomas from 
rhesus macaques were found to undergo transcriptional reprogramming between early (4weeks) 
and late (13weeks) time points in infection25.  In the second study, peripheral analyses in 
cynomolgus macaques revealed the greatest transcriptional change between 3 and 8 weeks post 
infection26.  Both of these profiling studies reiterate the variable and dynamic states occurring 
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both locally and systemically throughout infection and reinforce the importance that early events 
play in shaping clinical outcome27.  
1.1.3 The granuloma, a dynamic structure of bacterial containment and persistence 
The hallmark of human TB is the granuloma, an organized and localized aggregate of immune 
cells that consists of macrophages, lymphocytes, and other host immune cells and forms in 
response to persistent stimuli28.  In TB, these structures arise at the sites of infection and 
represent an active interchange between the host and pathogen.  The formation of a granuloma is 
crucial to adequately control and contain infection29,30, but may also contribute to early M. 
tuberculosis proliferation and dissemination31-33.  Human studies from over a half-century ago 
have revealed that in active disease and latent infection, granulomas exhibit morphological 
heterogeneity7,34.  In addition to the classic caseous granuloma, granulomas can be non-
necrotizing, neutrophil-rich, mineralized, or completely fibrotic30.  In nearly all of these 
instances, the basic granuloma architecture exhibits the following layout: a central acellular 
necrotic core, termed caseum, surrounded by a diverse population of macrophages, which is 
itself circumscribed by a lymphocytic cuff of CD4 and CD8+ T cells and B cells, and may have a 
peripheral fibrotic edge29,32.  Granulomas primarily contain macrophages at various stages of 
activation and T and B cells, but can also contain neutrophils, dendritic cells (DCs), and 
fibroblasts30,32 (Figure 2).  The important lesson learned from appreciating the heterogeneity of 
human TB granulomas is that each separate lesion represents a localized microenvironment that 
can be independently influenced by the quality of the localized immune response, the 
pathogenicity, state, and prevalence of the bacteria, the extent of immunopathology, and the 
overall host disease status35,36.  The interaction of all of these factors in the granuloma has yet to 
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be determined but does allow for speculation into how heterogeneous disease states can arise 
from varying lesion-specific dynamics, particularly in the early stages of infection. 
 
Figure 2. Archetypical caseous granuloma.  
A classic caseous granuloma from an infected macaque.  It is organized into an inner region (c) of necrotic caseum 
surrounded by a region (h) of histocytic macrophages that is encapsulated (granuloma periphery) by a cuff of T and 
B lymphocytes.  This lesion has a peripheral region of fibrosis (black arrow).  Image courtesy Edwin Klein, VDM.   
 
1.2 FIRST IMPRESSIONS MATTER: EARLY EVENTS IN MYCOBACTERIUM 
TUBERCULOIS INFLUENCE OUTCOME 
New vaccines against M. tuberculosis are essential for preventing infection, disease and 
transmission.  However, the host immune responses induced by an effective vaccine remain 
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unclear6.  Increasingly it has become clear that early events including early innate responses in 
infection are of major importance in the eventual outcome of the infection37,38.  Studying such 
events in humans is challenging, as they are occurring within the lung and thoracic lymph nodes, 
and any clinical signs of early infection are relatively non-specific.  Development of an effective 
vaccine requires a clear understanding of the successful (and detrimental) early host responses 
against M. tuberculosis, with the goal to improve upon natural immune responses and prevent 
infection or disease. 
M. tuberculosis infection generally progresses quite slowly, with active TB being 
diagnosed most commonly within the first two years of infection.  People often do not know 
when they are exposed or infected and therefore, studying early events of infection in humans 
can be challenging.  Nonetheless, some studies support that the earliest events in M. tuberculosis 
infection are critically important in dictating clinical outcome. First and foremost, the inoculum 
dose in animal models from mice to non-human primates influences the severity of infection, so 
that more bacteria delivered to the lungs results in a worse outcome.  In addition, data from 
nonhuman primate studies suggest that between 3-6 weeks post-infection, one can predict 
whether the animal will progress to active TB disease or remain latently infected 6 to 9 months 
later, based on the extent of early dissemination, serologic (ESR) and PET-CT features 
suggestive of more extensive inflammation39.  Thus, clinical course is at least in part dictated by 
the early innate and adaptive immune responses.  Indeed, efforts to understand the basis of 
protective immunity to M. tuberculosis infection are pushing us to look even earlier into the 
course of infection.  Clinical studies suggest that there are individuals who are highly exposed to 
M. tuberculosis but remain persistently tuberculin skin test negative, and thus presumably 
uninfected16,18.  These individuals raise the possibility that at still earlier points in the course of 
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infection, it is possible for the host to fully clear the bacteria and that this early bacteriocidal 
response could be harnessed through vaccination.    
1.2.1 Clinical Data on Early Infection 
There are major gaps in our understanding of the early events in M. tuberculosis infection in 
humans.  These stem from the difficulty in identifying the onset of infection, for which there are 
no good diagnostic tools.  The classic diagnostic test for M. tuberculosis infection is the 
tuberculin skin test (TST), which is a delayed type hypersensitivity response to a crude mixture 
of M. tuberculosis proteins and lipids known as purified protein derivative (PPD).  A more recent 
test for infection is the Interferon-Gamma Release Assays (IGRA), in which blood is stimulated 
with two M. tuberculosis-specific antigens and then assayed for IFN-γ by ELISA or ELISPOT. 
Both the TST and IGRA measure the T cell response to mycobacterial antigens, and therefore are 
not positive until a measurable T cell response is induced. Induction of measurable T cell 
responses to M. tuberculosis infection can be quite slow in tuberculosis.  It occurs in humans 
approximately 6 weeks post-infection40. In non-human primates and in guinea pigs, TST 
conversion occurs 4-8 weeks after exposure and infection41,42.  Although TST is not usually 
performed in mice, an older study showed that PPD+ skin test responses were observed at 4-6 
weeks post-infection43.  However, M. tuberculosis-specific T cell responses in lymphoid tissues 
can be measured as early as 2 weeks post-infection44.  Conversion of a negative to positive TST 
or IGRA result denotes recent exposure and infection.  Frequent TST or IGRA testing is 
necessary in clinical settings to establish an approximate time of infection, but by the time a T 
cell response is measurable, the early events in infection have already occurred.  The lack of 
simple diagnostic tests that can be used to identify infected individuals immediately after 
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infection makes it difficult to conduct rigorous studies on the course of early infection in 
humans.  
Despite these limitations, landmark studies were conducted by Poulsen in the Faroe 
Islands in the pre-treatment era of the 1930s and 1940s that provided critical insights into initial 
infection in humans40,45.  In these studies, a version of tuberculin skin testing was performed on 
nearly all of the 30,000 residents of the numerous villages in the Faroe Islands, and nearly all 
persons with active TB were known.  Thus, the local epidemiology of TB in each village was 
well documented, and since most villages were small, tracking individuals and obtaining detailed 
histories was possible.  New TST conversions were followed up closely, with particular attention 
paid to identifying the time of infection by determining the index case and the duration of 
exposure to that case by the newly infected individual, as well as clinical signs post-infection, 
including X-rays and fluoroscopy.  The first detailed description of these studies is a fascinating 
series of “case reports” documenting the duration of and time since exposure to an index case, 
skin test conversion, subsequent clinical manifestations, and outcome40.  In some cases, exposure 
to a person with active TB for less than 24 hours resulted in TST conversion and subsequent 
development of primary TB. TST conversion was generally evident by 6 weeks post-exposure. 
Interestingly, nearly all of the reported cases experienced a fever (termed “initial fever”) around 
the time of skin test conversion, and follow up indicated hilar adenopathy, with a number of 
subsequent cases of active TB and deaths. 
In a follow up study, Poulson rigorously analyzed early symptoms of infection and 
outcome45.  A total of 232 subjects (children and adults) who had TST conversions within the 6 
month interval of testing were followed for several years.  An additional 285 subjects who were 
selected as presenting with an initial fever in conjunction with recent skin test conversion were 
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also followed.  Of the 232 “unselected” subjects, 63% had an initial fever after infection, and the 
frequency was similar between adults and children.  The fever was of variable intensity and 
duration, though this was not predictive of disease outcome.  These findings suggest an initial 
inflammatory process in the majority of those infected with M. tuberculosis, regardless of 
infection trajectory (i.e. primary disease or containment).  Poulson documented other signs of 
initial inflammation associated with infection including elevated erythrocyte sedimentation rate 
(ESR), a non-specific sign of inflammation and erythema nodosum, an inflammatory process 
often linked to mycobacterial infection.  Elevated ESR was coincident with initial fever, and in 
most cases returned to normal within 2 months.  Even with the X-ray and fluoroscopy 
technology available at the time, hilar adenopathy, presumably signifying thoracic lymph node 
enlargement, was identified in 55% of subjects unselected for fever in the first two months post-
infection, with little increase in hilar lymph node involvement after this time.  Pulmonary 
infiltrates were observed within the first year in 27% of converters, which agrees with a separate 
study in Norway46.  These infiltrates were usually seen within 3 months of TST conversion and 
usually unilateral. Most of these infiltrates regressed over the next several months, and only 15% 
of those with infiltrates progressed to active TB.  However, when separated between adults and 
children, the authors find that 2% of children with infiltrates developed active disease whereas 
25% of adult converters with infiltrates progressed to TB suggesting that early pulmonary 
infiltrates in adult converters is linked with disease progression45.  
Importantly, the earliest stages of infection may also be associated with bacterial carriage 
in sputum.  For example, a recent study employing active case finding to estimate the prevalence 
of TB in household contacts revealed a stunningly high rate of asymptomatic carriage of M. 
tuberculosis bacteria in the sputum in household contacts, presumably more recently infected by 
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the incident case47.  Similarly, pediatric studies suggest that there can be an early period of 
bacterial “excretion” after infection, which subsequently can resolve and does not necessarily 
herald eventual tuberculosis disease48.  This supports a model in which an early period of 
bacterial growth is relatively common, even where the infection will subsequently be controlled.  
These studies provide evidence of an early evolution of the infection in the majority of 
those infected, including an inflammatory process, evidence of thoracic lymph node involvement 
and potentially also the presence of culturable bacilli in the airways or sputum.  Thus, the initial 
events in humans are not usually “silent” and suggest that the host immune response to initial 
infection is relatively robust.  As most infections do not progress to active TB, this immune 
response is often successful in restraining the infection, although it is apparently a matter of 
months before this containment is complete. 
These findings from human studies are recapitulated by our studies in macaque models of 
tuberculosis.  Cynomolgus macaques develop active TB or latent infection, defined clinically, 
following infection with <25 CFU M. tuberculosis strain Erdman42,49.  Using PET/CT imaging 
with fluorodeoxyglucose (FDG) as a probe, immunological assays, and clinical assessments, we 
have demonstrated that all macaques infected with a low dose of M. tuberculosis have an 
evolution of infection within the lungs, with granulomas visible by 2-3 weeks by PET/CT 
imaging39,50.  Thoracic lymph nodes are often enlarged or show FDG avidity within a few weeks 
of infection. Using culture of gastric aspirates and bronchoalveolar lavage (BAL) as surrogates 
for sputum cultures, 30% of infected monkeys were found to shed culturable M. tuberculosis 
within 2 months of infection, indicating bacilli in airways during acute infection49.  This was 
loosely correlated with outcome, with 90% of macaques that progress to active TB showing a 
positive gastric aspirate or BAL in the first two months of infection, compared to 44% of those 
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monkeys that would present with latent infection (unpublished data). ESR is very low in 
uninfected monkeys (normal <2mm).  Increased ESR within 60 days of infection was strongly 
correlated with eventual progression to active TB; ESR>15 in the first 2 months of infection 
correctly predicted outcome with 92% accuracy (unpublished data).  Coleman, et al. showed that 
formation of new granulomas between 3-6 weeks post-infection, and increased PET avidity in 
those granulomas, was associated with eventual development of active TB39.  Although 
radiographs are less useful in macaques than in humans and not as sensitive as PET CT, our early 
studies using x-rays suggested that early pulmonary infiltrates were observed in 60% of our 
macaques42, most of which went on to develop active disease.  The macaque data support the 
human data on early inflammatory responses following infection, but also suggest that the final 
outcome of primary infection is determined early by the ability of the host to control infection in 
the granulomas and prevent early dissemination. 
A more in depth study of granulomas from macaques demonstrated that the bacterial 
burden in the initial granulomas at 4 weeks post-infection is relatively high (~5 x 104 CFU) with 
minimal bacterial killing occurring36.  However, as the adaptive immune response is induced, 
bacterial killing in granulomas increases, dramatically reducing bacterial burden, and in some 
cases sterilizing the granuloma.  Indeed, even in monkeys that progress to active TB, an average 
of 30% of the granulomas are sterile36.  The specific factors that drive an individual granuloma 
towards a particular fate remain poorly understood, but are likely to reflect the contributions of 
both host and bacterial factors. 
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1.2.2 Early Granuloma Formation and Bacterial Dissemination 
What is known about the course of granuloma formation in people?  Our understanding of early 
granuloma formation is rooted in results from human autopsy series published by Georges 
Canetti in the 1955.  Based on his histopathologic examinations of 1500 autopsies, Canetti 
proposed that all tuberculous lesions proceed initially through an exudative and then a caseous 
phase.  He suggested that lesions then sit at a “crossroads”–some remaining solid and ultimately 
sclerosing and others softening, where softening of the caseum, not caseation per se, was the 
harbinger of active disease51.  At the time that he wrote, Canetti did not understand the basis of 
softening although in about half the cases, it was associated with an influx of neutrophils.  In a 
discussion that remains highly relevant today, he wrote51:  “This poses the question of whether 
an unknown factor orients the lesion from the outset toward liquefaction; that is, determines its 
fate from the earliest phases when the lesion may not be distinguished from another whose 
evolution will be ‘normal.’  On the other hand, one also often observes softening of lesions of 
long-standing radiologic existence; this is evidence of the potential danger of old caseous 
lesions.”   
Researchers have sought to better define and identify determinants of granuloma fate in a 
variety of experimental models.  Data from these models has supported many of Canetti’s 
observations (Figure 3).  Exploration of early granuloma organization and development in 
guinea pigs has shown that within 21 days there is evidence of caseation preceding initiation of T 
cell responses implicating both innate mechanisms and bacterial processes in early cellular 
death52.  Similarly, in macaques, the earliest granulomas isolated from the lungs (at 3 and 4 
weeks post-infection) are primarily caseous in nature53, where some of these lesions are expected 
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to progress but most will not, and indeed, some will be fully sterilized after the onset of adaptive 
immunity.    
 
Figure 3. Canetti model of granuloma evolution.  
Canetti granuloma formation and progression coupled with outcome of M. tuberculosis infection. Image used, with 
permission, Cadena et al27. Copyright (2016) American Association of Microbiology, USA.  
 
The first steps in the development of the granuloma, and the path to early caseation, have 
been elucidated using M. marinum in zebrafish.  These studies indicate that early macrophage 
death in the primary granuloma is linked to bacterial replication, dissemination, and secondary 
granuloma formation31,32.  Specific modulation of macrophage apoptosis and necrosis by the 
ecosanoid pathway, PGE2 and LXA4, respectively, early in infection has been shown to 
influence infection outcome54,55.  These studies extend the concept of the granuloma as a 
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protective host response to suggest that it also provides a niche for mycobacteria to establish 
robust infection.   
The events that dictate the fate of the granuloma after early caseation are less well 
understood.  M. tuberculosis expresses matrix metalloproteinases that can degrade collagen and 
facilitate tissue destruction56-58.  The relative contribution of these bacterial virulence factors to 
the softening of the caseum that Canetti described, as opposed to caseation per se, remains 
unclear.  It is possible that this reflects the effect of the enzymes responsible for the lipid 
mediators already implicated in TB disease, where alteration of activity is also expected to 
impact the linked lipid mediators of resolution of inflammation and neutrophil recruitment.  
1.2.3 What are the Critical Cellular Events in Early Infection? 
Our current understanding of the cellular events in early infection of M. tuberculosis draws on a 
number of in vitro model systems and in vivo small animal model studies.  Inhalation of a small 
number of M. tuberculosis via droplet nuclei from a person with active tuberculosis results in 
deposition of the bacilli into the alveolar space and initial contact and phagocytosis by alveolar 
macrophages59.  Following infection, an early influx of phagocytic cells including alveolar 
macrophages, neutrophils, and dendritic cells (DCs) arrive to this focus and begin to seed 
formation of a granuloma7,60.  Studies using a M. marinum zebrafish model helped to 
characterize the earliest cells recruited to the site of infection and showed that macrophages, not 
neutrophils, were the dominant phagocytosing cells in the first 4 days post infection61.  Murine 
studies with both M. tuberculosis62 and BCG63 suggest that there is early infection of alveolar 
macrophages, various populations of DCs, and neutrophils64.  At 2 weeks post infection, the 
lungs of C57BL/6 mice infected with ~100 CFU of M. tuberculosis Erdman revealed that the 
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predominant populations in the lungs are Ly6G+ neutrophils and F4/80+ macrophages64.   
Further characterization of the kinetics of lung recruitment within the first 2 to 4 weeks of 
infection in mice infected with GFP labeled M. tuberculosis revealed a diverse and dynamic 
interplay between host cells and bacteria62.  At 14 days post infection, myeloid DCs, alveolar 
macrophages, and neutrophils had the highest percentage of M. tuberculosis (GFP+) infected 
cells; by day 21, neutrophils and myeloid DCs had the highest percentages.  Similar observations 
of the mediastinal LNs determined that myeloid DC migration was the primary infected source 
during the initial stages of infections62. An excellent overview of these early cellular interactions 
is reviewed and modeled by O’Garra et al7 and summarized in Figure 4. These observations 
highlight the diverse range of early phagocytic responders to M. tuberculosis infection and 
implicate their initial influence on the progression of early disease and dissemination.   
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Figure 4. Early cellular response to M. tuberculosis.  
An overview of the early cellular interactions between host and bacterium following M. tuberculosis infection that 
culminate in formation of the tuberculosis granuloma.  
 
A recent review by Srivastava et al comprehensively assessed the diversity of these initial 
mononuclear cell subsets and detailed their contributions in tuberculosis65.  The authors 
evaluated the relative differences of each subset’s ability to both prime adaptive responses and 
control M. tuberculosis by reviewing each subset individually, drawing on in vitro, mouse, and 
human data.  Ultimately, the authors posit that the inherent functional differences of each subset 
likely contribute to the overall outcome of infection following potential skewing of one subset 
over the others.  Importantly, this hypothesis helps to bridge the observed diversity in cell types 
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with the resulting clinical variability observed in tuberculosis.  Building on this hypothesis, we 
propose that the interplay of these diverse cell subsets and M. tuberculosis in the initial stages of 
infection contributes to granuloma fate and heterogeneity36,66 which subsequently influences host 
outcome39.  From this, we hypothesize that the local differences driven by early host-pathogen 
interactions manifest as a spectrum of granulomas with varying capacities for containment and 
bacterial killing, which ultimately leads to different clinical outcomes.  As a point of speculation, 
it is possible that the activation status of the initial infected cell that seeds a granuloma could set 
the stage for inflammation, T cell recruitment, macrophage activation and eventual fate of that 
granuloma. 
1.2.4 Neutrophil activity is a strong correlate of the outcome of human infection with M. 
tuberculosis 
In recent years, it has become clear that neutrophil activity is a strong correlate of human TB 
disease state.  Studies of gene expression in the blood of people with active and latent TB 
revealed a signature of neutrophil driven IFN-β production in those with active disease23,67.  
Furthermore, neutrophils were the primary cell infected with M. tuberculosis in samples of 
human BAL fluid, sputum, and pulmonary cavities from with active TB cases68.  In addition to 
being a correlate of disease state, recent studies in small animal models suggest that neutrophil 
activity directly contributes to the progression to active disease.  For example, Dorhoi et al. 
sought to understand the role of micro-RNA223, which had been identified as a correlate of M. 
tuberculosis infection state in a large human cohort69.  Studying the function of this micro-RNA 
in mice, they found that it controlled neutrophil recruitment to the lung during infection by 
regulating the expression of key neutrophil chemoattractants including CXCL2, CCL3 as well as 
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IL-6.  In spite of these observations, the role of neutrophils in early infection remains 
incompletely understood.  In zebrafish, neutrophils contributed an early protective effect against 
M. marinum through NADPH-dependent oxidative killing70.  In mice infected with M. 
tuberculosis, early depletion of neutrophils reduced migration of DCs to lymph nodes and further 
delayed priming of antigen-specific CD4+ T cells71.  In this same study, DCs that ingested 
infected neutrophils migrated better in an in vitro transwell chemotaxis system than those that 
simply ingested free M. tuberculosis bacilli.  These findings suggest that neutrophil recruitment 
plays a causal role in disease progression with potentially both protective and destructive 
properties, which is likely dependent on their timing and magnitude of response.  
Recent data suggest that the human gene expression signature of active tuberculosis, 
neutrophil derived IFN-βexpression, reflects part of a broader signaling network that regulates 
the function of key immune players including macrophages, T cells and neutrophils72-74.  The 
signaling network includes cytokines, most notably Type I IFNs, IL-10, IL-1 and IL-1 Receptor 
Antagonist (IL-1RA), as well as lipid derived small molecule regulators of inflammation such as 
the eicosanoid prostaglandin E2 (PGE2).  Recent work by Mayer-Barber and colleagues suggests 
a cross-regulatory network in which Type I IFNs promote the production of IL-10 and IL-1RA, 
which in turn negatively regulate IL-1 expression and IL-1 dependent expression of PGE275.  In 
this model, PGE2 and IL-1 are protective and inhibit bacterial growth.  Altering this signaling 
network, for example by supplementing with PGE2 or increasing PGE2 by inhibiting 5-
lipoxygenase (5-LO) with the asthma drug, Zileuton, dramatically ameliorates infection outcome 
in mice.  The mechanism(s) by which this signaling network controls the outcome of TB 
infection in infected animals or humans is unclear.  These eicosanoids are important players in a 
cascade of lipid mediators that coordinate inflammation and the resolution of inflammation and 
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include the prostacyclins, leukotrienes, thromboxanes and resolvins76.  Importantly these lipid 
mediators are both synthesized by ---and have substantial effects on-- other key immune cells in 
the granuloma, including neutrophils.  The 5-LO product, LTB4, which has been implicated in 
zebrafish as an important driver of poor TB outcomes77,78, is a powerful neutrophil 
chemoattractant that serves to amplify primary danger signals and coordinate neutrophil 
recruitment.  Thus, it is likely that the profound effects of perturbing the Type I IFN-IL1-PGE2 
signaling network in mice reflect not only the impact on macrophage fate but also the arrival and 
function of neutrophils at the site of infection.     
1.2.5 T cells and beyond 
For a granuloma to function, T cells are required. The interactions between M. tuberculosis and 
the cells of the innate immune system clearly have profound consequences on the subsequent 
adaptive response.  The adaptive response is slow to emerge in M. tuberculosis infected hosts. 
Humans (and macaques) convert a tuberculin skin test, a measure of an adaptive T cell response, 
at approximately 6 weeks post-infection40,42.  T cell responses in blood can be detected in 
macaques between 4-6 weeks49, while a T cell response the lymphoid tissues of mice can be 
detected between 14-21 days post-infection44,79.  This delay in T cell response has been attributed 
to several factors, including a delay in delivery of bacteria or antigens to the thoracic lymph node 
for T cell priming. Although some studies have suggested that the delay is in part due to the low 
numbers of bacilli delivered to the host44, another study found that dose of infection did not 
appreciably influence the time to priming of an adaptive response80.  There may be specific 
bacterial factors that inhibit delivery of M. tuberculosis to the lymph node.  Evidence exists for 
both dendritic cells and CCR2+ macrophages as important players in transit of M. tuberculosis to 
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the lymph nodes for priming T cells81,82.  Whether the bacteria that end up in the lymph nodes 
come from the airways during early infection, or the lung granulomas once they are established, 
is not yet clear.  There is evidence from mice that dendritic cells can carry M. tuberculosis from 
airways to the thoracic lymph node81.  It is less clear where the CCR2+ macrophages are 
encountering the bacilli for transport to lymph nodes, but it appears more likely that these are 
lung parenchymal bacteria.  Nonetheless, most mouse studies have shown that M. tuberculosis 
bacilli must be in a lymph node to initiate priming of a T cell response44,79, although mice devoid 
of lymph nodes and spleen were capable of priming T cell responses in the lungs83. 
Alteration of macrophage apoptosis, driven by the balance of LXA4 and PGE2 signals, 
alters CD8+ T cell cross-priming by DCs55.  These seminal findings provide insight into earlier 
observations of M. tuberculosis-specific impairment of antigen presentation and defects in Ag85-
specific CD4+ T cell expansion in spite of enhanced airway-LPS stimulated macrophage 
recruitment to the lung and increased migration of DCs to the draining LNs44.  In addition to 
delaying potent T cell responses, recent work in mice has proposed that preliminary M. 
tuberculosis dissemination utilizes CD11c+ DCs to seed new granuloma formation84.  
Investigating both intraperitoneal BCG and aerosol H37Rv infections in C57Bl/6 mice, Harding 
et al demonstrated that inflammatory DCs are a possible source of bacterial spread after acute 
infection as these cells are frequently arrested during their migration to the lymph nodes 
following interaction with antigen-specific T cells.  These areas of infected DC-T cell capture 
generate new foci of inflammation that can either formulate new granulomas or extend 
preexisting structures depending on distance traveled.  Collectively, these findings support the 
view that virulent M. tuberculosis actively subverts the early host immune response by 
modulating preliminary macrophage death to delay the onset of potent adaptive responses and 
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utilize trafficking DCs to further dissemination.  These adaptations are likely crucial for M. 
tuberculosis to establish a foothold for infection given its slow growth.  
In considering potential important drivers of granuloma resolution – or the softening of 
the caseum observed by Canetti-- it is also interesting to note that the T cell response directly 
regulates the innate inflammatory response.  Nandi and Behar have shown in the mouse model 
that IFN-γ produced by CD4+ T cells inhibits neutrophil recruitment such that influx of 
neutrophils was reflective of a failed Th1 response74.  These results were extended by Mishra and 
colleagues who showed that IFN-γ dependent nitric oxide production suppressed IL-1 production 
by inhibiting assembly of the NLRP3 inflammasome85. 
In addition to phagocytes, M. tuberculosis likely encounters other cell types, cytokines, 
and innate defense molecules in the airways during initial infection.  Mucosal associated 
invariant T cells (MAITs) are CD3+CD8+ (or double negative) T cells that have T cell receptors 
encoded by the TRAV1/1 genes and are restricted not by the classical MHC molecules, but by a 
non-classical molecule MR-1 (reviewed in 86).  These cells are at higher frequency in blood and 
mucosal sites in humans compared to mice.  MAITs emerge from the thymus with effector 
capabilities and thus can be considered to be early responders to bacterial, including M. 
tuberculosis, infections. MAITs respond to cells infected with bacterial pathogens without prior 
exposure to that pathogen, produce the cytokines IFN-γ and TNF, and are cytotoxic.  Although 
the range of microbial ligands recognized by these “innate” T cells is not known, it was shown 
that MAITs recognize microbe derived riboflavin metabolites87.  Recent studies suggest greater 
TCR diversity than originally appreciated, and thus MAITs are likely to recognize other 
microbial-derived ligands88.  In MR-1 deficient murine models, MAIT cells were associated with 
early protection against bacterial pathogens, including mycobacteria89.  Thus, these cells may act 
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as early sensors of M. tuberculosis infection in airways, and provide early cytokines to activate 
macrophages against this infection. 
Other innate cells, including Natural Killer (NK) cells, may also play a role in early M. 
tuberculosis infection.  NK cells are strong producers of IFN-γ and TNF and can also be 
cytolytic for M. tuberculosis-infected macrophages38.  Mycolic acids are ligands for NK cells, 
and human studies have shown substantial variability in responses of NK cells to extracellular M. 
tuberculosis90, suggesting that the capacity of NK cells to recognize and respond to M. 
tuberculosis could contribute to early innate resistance to infection.  
In addition to cells, the airways also have molecules such as surfactants and hydrolases 
that have been proposed as potential modulators of M. tuberculosis infection. Human surfactant 
proteins A and D bind to M. tuberculosis91.  Surfactant protein A up-regulates expression of the 
mannose receptor on human macrophages92, an important receptor for binding to M. 
tuberculosis, and modulates the inflammatory response of macrophages93.  Human surfactant 
protein D directly binds to M. tuberculosis reducing uptake by macrophages94.  However, mice 
deficient in both surfactant proteins A and D were not impaired in control of low dose aerosol 
infection with M. tuberculosis95.  Antimicrobial peptides, such as cathelicidin (LL-37), are also 
present in airways96 and have been shown to increase the pro-inflammatory functions of 
macrophages and the killing of intracellular M. tuberculosis97.  Intratracheal administration with 
synthetic peptides mimicking LL-37 in mice reduced M. tuberculosis bacterial burden98.  There 
is substantial evidence that Vitamin D is important in resistance to tuberculosis99-102, and this 
appears to be in part due to induction of LL-37103,104.  
Antibodies are an obvious acquired immune response that might modulate the course of 
infection in airways.  As part of the acquired immune response, pathogen specific antibodies 
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cannot be predicted to prevent initial infection in previously unexposed hosts, though it is 
possible that they could serve this function in the case of repeat exposure or vaccination.  More 
importantly, although M. tuberculosis infection induces strong antibody responses, there is only 
scant experimental evidence that antibodies can prevent the initial establishment of infection. 
Passive transfer of antibodies specific to some cell wall antigens has been reported to confer 
protection against disease in a mouse model but the effect was inconsistent.  However, there are 
clear data that antibodies can change the interaction of the bacterium with macrophages in a 
variety of ways105,106; bacterial opsonization alters vesicular trafficking and macrophage 
signaling and interaction of antibodies with activatory or inhibitory Fc receptors on macrophages 
can modulate macrophage function105.  Beyond their classical functions, antibodies have the 
capacity to mark the infected macrophage as aberrant and recruit the responses other innate 
immune cells—thus making them potential modulators of the local immune response.  However, 
whether antibodies are present in the airways in sufficient quantities to modulate initial infection 
remains unclear, and a source of substantial investigation. 
In summary, there are a variety of cells, cytokines, and molecules present in airways that 
can modulate the initial response of the host to M. tuberculosis infection.  These factors may 
prevent infection completely, limit initial establishment of granulomas, modulate the local 
environment of newly emerging granulomas or increase the induction of T cell responses against 
M. tuberculosis.  Changes in these factors could increase susceptibility to initial infection as 
well. Further studies will be necessary to more fully understand the relative contributions of 
these factors to modulation of initial infection. 
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1.2.6 Lessons from Clinical Isolates of M. tuberculosis 
It is highly likely that bacterial factors drive differences in granuloma fate as well as host factors.  
Using barcoded bacteria to track to origins of the bacterial populations in individual lesions, we 
have shown that most pulmonary granuloma arise from one progenitor bacterium36 and genetic 
polymorphisms arise and become fixed in the bacterial populations of isolated granuloma107.  
These data are consistent with historical data indicating that within a given individual, bacteria in 
one lesion can acquire drug resistance independently of the bacterial populations in other 
lesions108.  These data reinforce the concept that granuloma evolve relatively independently 
within the same host.    
Many bacterial virulence factors have been identified through forward and reverse 
genetic approaches in experimental systems.  However, it is not clear whether any of these might 
be modulated to alter interactions with the host in a lesion specific fashion and thus contribute to 
the different lesional trajectories we and others have observed36,39,109.  This question has not yet 
been addressed through lesion specific analyses, for example, transcriptional profiling of 
granuloma bacterial populations, which is experimentally challenging given the relatively small 
number of bacteria in many lesions.   
It is likely that the different virulence manifestations of clinical strains will shed some 
light on the bacterial pathways that flexibly alter interactions with the host.  Six distinct lineages 
have now been defined based on sequence differences110.  There is mounting evidence that this 
genetic diversity generates clinically relevant phenotypic variation and impacts infection 
outcome.  Strains have been shown to differ in terms of their mortality, pathologic manifestations 
and immune responses in mice and in human macrophages111-114.  Despite the mounting evidence 
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that the genetic diversity of M. tuberculosis has clinical consequences, few concrete links 
between genotype and phenotype have been identified.  The best studied association has been 
between the presence of phenolic glycolipid biosynthesis and the hypervirulent phenotype and 
immunosuppressive properties associated with Lineage 2 strains115.  In M. marinum infection of 
zebrafish, phenolic glycolipid promotes the recruitment of permissive macrophages to the site of 
infection and is required to establish robust infection116.  In modulating initial macrophage 
recruitment114 as well as macrophage death pathways (discussed above), M. tuberculosis is likely 
influencing multiple early host interactions to affect inflammatory programs, granuloma fate, 
dissemination, and ultimately infection outcome.  
It remains unclear whether bacterial expression of virulence lipids varies in a lesion 
dependent fashion.  It is interesting to note, however, that production of another virulence lipid, 
PDIM, is one mechanism to resolve propionyl-CoA toxicity during growth on fatty acids117,118.   
PDIM biosynthesis is both required for bacterial survival in mice and macrophages119,120 and 
PDIM has been proposed, based on work in M. marinum, to directly cloak TLR2 ligands116.   
Thus, it is possible that the regulatory effects of central carbon metabolism—where more or less 
PDIM may be produced depending on carbon source availability—provides an energy efficient 
mechanism to link host environment with bacterial virulence and reinforce the trajectory of any 
given lesion after it is established by very early host events. 
Establishment and progression of M. tuberculosis remains somewhat of a mystery in 
humans.  However, a deeper understanding of the early events in tuberculosis is essential to 
identifying new and effective strategies of preventing active TB. The best vaccine would prevent 
establishment of the infection, or at the very least, prevent early dissemination of individual 
granulomas.  Understanding the early airway and lung responses to this infection is crucial, as 
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this is where control must occur.  There are a variety of host cell types and molecules, as well as 
bacterial factors, which interact in early infection, as described here.  Building on this knowledge 
will move the field of vaccines against tuberculosis forward. Without a clear understanding of 
the early processes that vaccines must prevent or limit, and the host responses that can be 
harnessed for protection, we cannot expect a vaccine to succeed against this complex and 
evolved pathogen.  
1.3 MODELING HETEROGENEITY AND SINGLE LESION DYNAMICS IN THE 
MACAQUE MODEL OF MYCOBACTERIUM TUBERCULOSIS 
Animal models of M. tuberculosis are critical to dissect features of infection pathogenesis, TB 
pathology and immunology, and bacterial virulence.  Several animal models have been used over 
the past decades to study TB including zebrafish121, mice122, and nonhuman primates123,124.   
Each system possesses both benefits and limitations in modeling TB and while none perfectly 
capture human M. tuberculosis infection, they all contribute to our understanding of this disease.  
The model recognized to best recapitulate the multiple facets of variability in TB is the 
cynomolgus macaque.  While ethical considerations, limited reagents, and cost may detract 
general use, the range of outcomes both clinically and pathologically is remarkably similar to 
that observed in humans49,125.  There is a 50:50 ratio of latent infection and active disease in adult 
cynomolgus macaques infected with low dose (<25) virulent M. tuberculosis Erdman.  
Importantly, within these binary definitions, infected macaques recapitulate the entire spectrum 
of human disease both at the local, lung and overall host level including the ability to reactivate 
 29 
latent infection following immune suppression with SIV126, anti-TNF127 or anti-CD4 
treatment128.     
Given the recent seminal finding that the majority of M. tuberculosis lesions in NHPs 
arise from a single bacillus36, genetically tagging individual bacilli provides an unparalleled 
ability to track the outcomes of discrete lesions within a single host. This dissertation utilizes this 
molecular barcoding tool to examine lesions in multiple dimensions by linking immunology, 
histology, and radiographic imaging to specific lesions in a novel manner.  Collating these 
different facets of TB biology allows for the re-creation of infection on a lesion-by-lesion basis 
and will enhance understanding into the early events that occur post challenge by generating an 
overall picture of M. tuberculosis infection in vivo.  Furthermore, barcoding individual M. 
tuberculosis permits the study of sequential infections and exposures in a single host. These are 
crucial aspects of M. tuberculosis infection that have yet to be thoroughly explored. 
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2.0  STATEMENT OF INTENT AND SPECIFIC AIMS 
It is estimated that a third of the world’s population is infected with M. tuberculosis, the acid-fast 
bacillus responsible for tuberculosis (TB). A tenth of this infected population will develop 
primary active disease with the remaining 90 percent containing the infection as latent TB.  Of 
those individuals with latent TB, ~5-10% will reactivate to active TB disease over their lifetime.  
Epidemiologic studies of tuberculin skin test (TST) screening in highly endemic countries have 
further revealed persistent non-responders, despite high exposure to M. tuberculosis, hinting of a 
potentially TB resistant human reservoir.  The complex heterogeneity that is responsible for this 
observed human variability to TB remains poorly understood.  It is likely that the human TB 
spectrum stems from early immunologic and host-bacterium interactions that orchestrate both the 
susceptibility to infection, progression of disease, and risk of reactivation.  In probing early 
events in M. tuberculosis infection, we hope to identify key phases of infection that control 
bacterial dissemination and correlate with protection, which can be subsequently exploited for 
novel vaccine development and drug design.  In this dissertation, we examine how early events 
in M. tuberculosis infection relate to host outcome by addressing questions of bacterial 
dissemination and reinfection using individually barcoded bacteria in the non-human primate 
(NHP) model of TB. We are also evaluating the earliest microbial interactions in the lung by 
examining the influence of M. tuberculosis on the lung microbiome, particularly as a function of 
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pulmonary inflammation. Together, these studies will help elucidate the contribution of early 
events on host outcome.   
Primary hypothesis: We hypothesize that early interactions between M. tuberculosis and host 
immune components drive local lesion heterogeneity and that these initial events influence 
infection outcome.  To address this hypothesis, we propose the following Specific Aims: 
2.1 SPECIFIC AIM 1: DETERMINE FEATURES CONTRIBUTING TO 
BACTERIAL DISSEMINATION IN M. TUBERCULOSIS INFECTION AND EXPLORE 
HOW EARLY INTERACTIONS BETWEEN HOST AND BACTERIA MODIFY 
BACTERIAL SPREAD  
We will infect a cohort of cynomolgus macaques (Macaca fascicularis) with a library of 
individually barcoded M. tuberculosis Erdman (~25 CFU) to track bacterial fate post challenge.  
These identity tags enable us to correlate lesion development with M. tuberculosis dissemination, 
infection progression, disease presentation, and lesion heterogeneity. Coupling the roadmap of 
infection from tagged M. tuberculosis (identity) with serial 18[F]-fluorodeoxyglucose (FDG) 
PET/CT imaging (timing) and cumulative bacterial burden (granuloma fate), we aim to unravel 
events in early infection critical to productive dissemination. 
Hypothesis: Early granulomas that are highly inflammatory (FDG avid) will be more 
likely to contribute to productive (CFU+) secondary lesions.  
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2.2 SPECIFIC AIM 2: DETERMINE HOW AN ONGOING M. TUBERCULOSIS 
INFECTION MODULATES SECONDARY INFECTION: PROTECTION OR 
EXACERBATION? 
Surprisingly little is known about the protective or pathogenic potential of a prior, ongoing M. 
tuberculosis infection on a subsequent exposure or infection.  Addressing this question is crucial 
to the development of effective vaccines. We will examine the impact of prior infection on 
reinfection in TB by infecting macaques with two different libraries of barcoded M. tuberculosis.  
Each library will have a unique library-specific tag to differentiate primary and secondary 
granulomas.  In two successive, low-dose (>25 CFU) infections, we will investigate whether an 
ongoing infection assists host clearance by enhancing TB immunity or undermines host defense 
by exacerbating host immunopathology.  
Hypothesis: Primary infection enhances protection to secondary infection by eliciting 
immune responses that limit early bacterial dissemination and augment bacterial killing 
in secondary granulomas.  
2.3 SPECIFIC AIM 3: DETERMINE HOW M. TUBERCULOSIS INFLUENCES THE 
LUNG MICROBIOME IN THE MACAQUE MODEL OF TUBERCULOSIS 
The specific interactions of the lung microbiota with M. tuberculosis early in infection are 
entirely unexplored.  Studies on other infections that examine immunity and the microbiome 
suggest that there are important exchanges that occur between these entities that influence the 
immunological landscape by altering immune regulation and inflammation in both local and 
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systemic contexts129.  We will assess if M. tuberculosis modifies the lung microbiome in 26 
infected macaques by serially comparing infected and uninfected lobes over the course of 
infection looking for changes in abundance and diversity as a function of pulmonary 
inflammation.  Since we have robust markers of disease progression using PET/CT as a measure 
of lung inflammation39,109, we will determine whether there is a correlation between the duration 
of change in lung microbiome in response to M. tuberculosis infection and the outcome of 
infection, gaining power from the serial sampling of individual animals.  We reasoned that the 
increased inflammation in animals that are progressing to active TB is likely to have a sustained 
interaction with the microbiome, while the animals that are controlling the infection early, and 
therefore have reduced inflammation, are less likely to have a sustained change in microbiome 
composition.  Successful completion of this aim will demonstrate the relationship of the structure 
of microbial communities to M. tuberculosis infection and progression of infection, define 
changes in the structure of lung microbial communities over time, and determine the relationship 
of microbial communities to systemic inflammatory biomarkers.  In examining some of the 
earliest relationships between M. tuberculosis and the lung microbe milieu, we aim to better 
understand how the initial lung context may influence host outcome and host variability in TB.  
Hypothesis: We hypothesize that lung inflammation from M. tuberculosis influences the 
variability and diversity of the lung microbiome in the infected lobe of macaques. 
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3.0  DIGITALLY BARCODING MYCOBACTERIUM TUBERCULOSIS REVEALS IN 
VIVO INFECTION DYNAMICS IN THE MACAQUE MODEL OF TB 
This chapter is adapted from the accepted manuscript: 
Constance J. Martin*, Anthony M. Cadena*, Vivian W. Leung, Philana Ling Lin, 
Pauline Maiello, Nathan Hicks, Michael R. Chase, JoAnne L. Flynn# & Sarah M. Fortune#. 2017. 
Digitally barcoding Mycobacterium tuberculosis reveals in vivo infection dynamics in the 
macaque model of tuberculosis. mBio 8:e00312-17. *Co-first authors, both authors contributed 
equally to this work; #Corresponding authors 
3.1 IMPORTANCE 
Classically, M. tuberculosis infection was thought to result in either latent infection or active 
disease.  More recently, the field has recognized that there is a spectrum of M. tuberculosis 
infection clinical outcomes.  Within a single host, this spectrum is recapitulated at the granuloma 
level, where there can simultaneously be lesional sterilization and poorly contained disease.  To 
better understand the lesional biology of TB infection, we digitally barcoded M. tuberculosis to 
quantitatively track the fate of each infecting bacterium.  By combining this technology with 
serial PET-CT imaging, we can dynamically track both bacterial populations and granuloma 
trajectories.  We demonstrate that there is little constraint on the bacterial population at the time 
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of infection.  However, the granuloma imposes a strong bottleneck on dissemination, and the 
subset of granulomas at risk of dissemination can be distinguished by physical features.  
3.2 INTRODUCTION 
Tuberculosis (TB) poses a threat to global health, responsible for more than 10 million new cases 
of active disease and nearly 2 million deaths in the last year130.  However, these recognized cases 
of TB disease reflect only a small fraction of M. tuberculosis infections, most of which result in a 
spectrum of outcomes that are clinically silent and collectively referred to as latent TB 
(LTBI)2,10,131.  These different courses of infection are characterized by a range of bacterial 
burdens and pathology, and correlate with reactivation risk14,21,22,49.  Recently, the field has 
focused on early interactions between host and bacterium as potential drivers of the variable 
outcomes of M. tuberculosis infection27.  However, new tools are needed to dissect the local 
biology of M. tuberculosis infection, especially in the non-human primate model (NHP), whose 
strengths are that it recapitulates the variable course of human infection and produces individual 
granulomas with pathology very similar to that found in humans49,132,133. 
Dissection of lesion course in macaques has been transformed by the use of positron 
emission tomography coregistered with computed tomography (PET/CT) and a 18F-
fluorodeoxyglucose radiotracer (18[F]-FDG), and validated in humans21,39,109.  Using this 
approach, we previously demonstrated that formation of disseminated lesions early after 
infection is associated with development of active disease whereas limited early dissemination is 
associated with maintenance of clinically latent infection, suggesting that early dissemination is 
critical in determining host outcome39.  From these studies, it was unclear whether early 
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dissemination was the result of a global defect in immunity or due to loss of control by a single 
lesion.  We have also shown that granulomas follow unique trajectories even within individual 
macaques as evidenced by differences in killing efficacy132.  Thus, we hypothesized that 
individual granulomas might similarly vary in their risk of dissemination.   
We have also shown that most lesions harbor the progeny of a single bacterial founder.  
However, this study was limited to very early time points (~4 weeks post-infection) and so did 
not assess the dynamics of dissemination132.  Moreover, as the previous study only used a panel 
of 8 bacterial strains, it did not allow us to unambiguously resolve the subsequent fate of each 
bacterium following infection.     
To address the lack of tools available to answer these critical biological questions, we 
developed a genome barcoding system, allowing us to track the fate of each infecting bacillus.  
The population dynamics of other pathogens have been tracked by assessing change in genetic 
composition of a population, leveraging either natural or artificially introduced genetic 
variation134.  However, these infection models are typically characterized by a relatively large 
infecting inoculum and wide bottlenecks that make tracking of individual bacteria or viruses in a 
population infeasible, and instead investigators have tracked changes in the distribution of 
diversity in the population to estimate bottleneck size.  By contrast, TB is a paucibacillary 
infection, where inocula of <20 organisms successfully establish infection, allowing us to track 
infection dynamics by directly following the fate of each bacterium that establishes infection.  To 
do this, we developed a complex library of digitally barcoded M. tuberculosis such that each 
infecting organism carries a unique and quantifiable sequence identifier.  In parallel, we 
developed a robust Python algorithm to reliably discriminate bacterial barcodes.  By combining 
this barcoding system with serial 18[F]-FDG PET/CT in a macaque model, we provide the first 
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quantitative map of within-host bacterial population dynamics focusing on M. tuberculosis 
infection and dissemination.  
3.3 MATERIALS AND METHODS 
3.3.1 Barcode generation 
Primers  (CM29/CM30 – see primer table, Supplementary Table 6) using a string of degenerate 
bases were used to amplify qTags135 from parent vectors and were restriction enzyme-digested 
and cloned into pJeb402 with KpnI and XbaI. Each library (single qTag) was constructed in E. 
coli and plated at 4x coverage before plates were scraped, maxi-prepped (Qiagen) and 
transformed into M. tuberculosis Erdman or M. smegmatis mc155 at 4x coverage.  Libraries were 
then scraped, passed through a 5μM filter (Millex) and sonicated for single cell suspension and 
mixed at equal OD600 to generate infectious libraries containing a pool of three Library IDs. 
3.3.2 Sequencing 
Bead beaten and phenol:chloroform purified genomic DNA was diluted to 10ng/uL, and  
amplified using Phusion polymerase through two rounds of PCR of 12 cycles each.  Primers are 
indicated in primer table.  Fragments of the appropriate size were gel purified, quantified using 
Clonetech NGS kit and sequenced on an Illumina Miseq using V2 chemistry.   
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3.3.3 Macaque infections, PET/CT imaging, and tissue excision 
Four adult cynomolgus macaques (Macacca fasicularis) were obtained from Valley Biosystems 
(Sacramento, California) and screened for M. tuberculosis and other comorbidities during a 
month-long quarantine.  Each macaque had a baseline blood count and chemical profile and was 
housed according to the standards listed in the Animal Welfare Act and the Guide for the Care 
and Use of Laboratory Animals. All animals were infected with barcoded strain Erdman M. 
tuberculosis via bronchoscopic instillation as previously published49,125 and received an 
inoculum of 11±5 CFU (determined by plating a sample of the inoculum and counting CFU after 
3 weeks).  All animals were followed with serial 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]-FDG) 
PET/CT imaging as formerly described39,109,132 to identify and track lesion formation and 
progression over time (Table 1).  As before, lesions were individually characterized by their date 
of establishment (scan date), size (mm), and relative metabolic activity as a proxy for 
inflammation ([18F]-FDG standard uptake normalized to muscle [SUVR]).  Lesions > 1mm can 
be discerned by our PET/CT equipment. To avoid barcode cross-contamination, individual 
granulomas were separately excised and processed using the animal’s pre-necropsy scan as a 
guide for identity and location.  
3.3.4 Isolation and preparation of bacteria from tissue samples 
Following removal at necropsy, each lesion was homogenized and plated for bacterial burden on 
7H11 agar supplemented with oleic albumin dextrose catalase (OADC).  A small portion of 
homogenate was frozen for CEQ analysis (below).  After a 3-week incubation, the plates were 
counted for CFU and colonies were pooled and scraped into 7H9 supplemented with OADC and 
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20% Tween 80. Each plate was scraped into a separate tube and frozen in 5mL of 7H9 at -80°C 
to await genomic DNA extraction and sequencing.   
3.3.5 Extraction of M. tuberculosis genomes and chromosomal equivalent quantification 
(CEQ) 
M. tuberculosis genomic extraction and CEQ quantification was performed as previously 
published22,132.  Briefly, gDNA was extracted with phenol:chloroform:isoamyl alcohol (25:24:1, 
Invitrogen) with an intermediate bead beating step using 0.1mm zirconia-silica beads (BioSpec 
Products, Inc.).  CEQ was assessed relative to a serially diluted standard curve of M. tuberculosis 
genomic DNA using quantitative real-time PCR preformed in triplicate on an iQ5 Multicolor 
Real-Time PCR Detection System (Bio-Rad Laboratories, Inc.) and a 384-well 7900HT Fast 
Real Time PCR System (Applied Biosystems).  Quantification of CEQ used the previously 
published primer-probe mixture and TaqMan Universal Master Mix II (ThermoFisher 
Scientific). Acceptable real-time PCR efficiency for each run was kept between 90%-110%. 
3.3.6 Bioinformatics analysis 
Data were analyzed using a custom Python pipeline available on GitHub 
(https://github.com/sarahfortunelab/barcodetracking).  The pipeline iterates through the raw 
FASTQ files generated from Illumina sequencing for each indexed sample.  We first identify 
library ID, barcode and molecular counter features using constant “handle” sequences as search 
motifs. We then filter data to obtain high-quality reads that: 1-have all features present; and 2- 
have a maximum probability of base calling error of 0.001 (equivalent to a minimum base 
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quality score of least 30 or Phred 63).  As an additional check, we grouped reads that passed 
quality control and counted molecular counter copies to check the extent of skewing.  For each 
sample, we also tallied the number of unique molecular counters for each sequence combination 
and normalized counts to the total molecular counts in the sample.  Using the aforementioned 
percentage counts as a metric for library-ID-barcode abundance, we computed the true-false-
determining threshold in the pipeline using a recursive approach.  In each round, we first 
computed and sorted the relative abundance in descending order. Second, we iterated through the 
barcodes that passed the previous threshold and, for each, eliminated less-abundant variants that 
differed by one position from the former.  Third, we calculated the threshold dividing true and 
false barcodes using a modified concavity approach.  Once the threshold reached a stable point, 
we applied the final threshold to return the set of true barcodes. 
3.3.7 T cell flow cytometry and intracellular cytokine staining 
At necropsy, granulomas were processed intro single cell suspensions with sterile PBS.  Portions 
of these suspensions were used for T cell profiling and cytokine analysis.  Tissue suspensions 
were stimulated with Mtb CFP10 and ESAT 6 (BEI Resources, Manassas, VA) and Brefeldin A 
(GolgiPlug, BD Biosciences) in RPMI (Lonza, Walkersville, MD) supplemented with 1% L-
glutamine and 1% HEPES (Sigma, St. Louis, MO) for 3.5 hours.  The final concentration of 
Mtb-specific peptides was 2.5μg/mL.  Cells were first stained with LIVE/DEAD Fixable Blue 
Dead Cell Staining Kit (ThermoFisher Scientific) for viability and then stained with the T cell-
specific marker, CD3, using the anti-human CD3 (clone SP34-2, BD Biosciences) antibody in a 
standard FACs buffer. Following surface staining described above, the cells were fixed and 
permeablized (BD, Cytofix/Cytoperm) and washed with BD Perm/Wash buffer (BD, 
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Biosciences).   Incubations were preformed according to manufacturer recommendations.  Cells 
were then stained with the following intracellular cytokine stains: anti-human IFN-γ (clone B27, 
BD Biosciences), anti-human TNFα (clone Mab11, eBiosciences), anti-human IL-2 (clone MQ1-
17H12, BD Biosciences), IL-6 (clone MQ2-6A3, BD Biosciences), anti-human IL-10 (clone 
JES3-9D7, eBiosciences), and anti-human IL-17A (clone eBio64CAP17, eBiosciences).  Flow 
cytometry was preformed on a LSR II (BD) and analyzed using FlowJo Software ver. 9.9.5 
(Treestar Inc., Ashland, OR).  Size (FSC) and granularity (SSC) were used to isolate the 
lymphocyte population at the cytometry.  All cytokine data presented are gated on CD3+ T cells. 
3.3.8 Statistical analysis 
Statistical analysis was performed in Graphpad Prism, JMP and R, significance was found when 
p < 0.05.   
3.4 RESULTS 
3.4.1 Barcoded bacterial library generation 
We engineered a library of digitally barcoded plasmids that we introduced into M. smegmatis 
and M. tuberculosis Erdman.  The ‘barcode’ consists of a random 7-mer and adjacent 75-mer 
library identifier tag stably inserted into the bacterial chromosome135 (Figure 5A).  Using this 
approach, we were able to generate libraries of roughly 50,000 uniquely identifiable bacteria, 
ensuring a <2% chance that a barcode would be represented twice if 20 bacteria are randomly 
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selected.  To quantitate barcodes via sequencing, the barcode is amplified from isolated genomic 
DNA in two rounds of nested PCR steps.  In the first round, a pool of four primers with a 
degenerate variable length spacer anneals a random 9-mer ‘molecular counter’ that allows us to 
enumerate PCR templates rather than amplicons136.  The degenerate variable length spacer, or 
“phasing region”, introduces sequence variability necessary for Illumina based sequencing of 
relatively low complexity libraries 137.  The second round of PCR completes the addition of 
sequencing adapters and multiplexing indices.  Using this sequencing approach, we confirmed 
the diversity of the M.tuberculosis Erdman library and found that most barcodes were present at 
similar abundances (Figure 5B).  A few sequences appeared over-represented, however, these 
represented only 0.5% of the total library and were not identified in any NHP used in this study.   
Concurrently, we developed a custom Python pipeline, BARTI, to identify barcodes from 
Illumina sequencing data in complex biological samples (i.e. granulomas), where both sequences 
and number of barcodes in a sample are unknown.  The challenge in reading out randomized 
DNA barcodes is that errors inherent in sequencing create uncertainty in identifying unique 
barcode sequences.  In previously published genomic barcoding approaches, this challenge was 
addressed by using only arrayed libraries of known barcodes, such that exact or near-exact 
sequence matching could be enforced138.  However, this approach significantly constrains the 
number of unique individuals represented in a population and precludes unambiguously tracking 
individual bacteria.  In sequencing approaches where unknown barcodes are used, error 
correction methods have been developed to discriminate false sequences from true139,140 but the 
best approach to high precision barcode counting is unclear. 
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Figure 5. Barcode structure and pipeline validation. 
A.  Barcode structure in the M. tuberculosis genome (top), and after preparation for sequencing (middle).  Schema 
of the BARTI pipeline for barcode identification, thresholding and counting.  B.  Abundance of individual barcodes 
in a single library.  C.  Number of barcodes counted using BARTI from known number of barcoded Mycobacterium 
smegmatis colonies at a read depth of >100,000.  D.  Ratios of barcodes counted using BARTI (actual) from known 
mixtures of barcode-containing plasmids mixed at indicated ratios (expected) and sequenced at a read depth of 
>100,000.  Dashed line is linear regression, R2 is Spearman correlation. 
 
To define the analytic path that provided the most accurate barcode quantitation, we 
arrayed single colonies of barcoded M. smegmatis, generated and sequenced pools of known 
numbers of colonies.  We expected that the number of barcode sequences identified should be 
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equal to the number of colonies used in that sample’s preparation.  Without error correction, as 
with other iterations of genome barcoding technology138,139, a much larger number of barcode  
sequences were identifiable in the sequencing data than were present in the input library.  
Strict read-quality filtering eliminated many, but not all, suspected erroneous sequences.  
Distance errors, wherein one or more bases in a barcode sequence are erroneously called, are 
common to these types of sequencing data.  Often algorithms are applied to correct distance 
errors by condensing sequences that differ by one base to the dominant sequence in order to 
maintain the greatest read depth possible141,142.  However, we found that condensing barcodes 
that differed by a single base in some cases skewed the estimation of barcode number.  Thus, we 
chose to discard sequences that differed by one base from a more abundant barcode.  This 
processed pool of barcode sequences still contained two populations of barcodes, abundant and 
putatively “true” and rare and putatively “false” barcodes representing persistent erroneous 
sequencing. By rank ordering the barcode sequences by template counts and taking the second 
derivative of the slope between each barcode to the next lesser abundant barcode, we found that 
the maximally negative point along this line described an inflection point that accurately 
separated expected number of barcodes from sequencing artifact.  Using this analytic approach, 
we accurately quantitated the number of known bacterial barcodes in the pooled mixtures of 
arrayed mycobacterial colonies across a range of sequencing read depths (Figure 5C and 
Supplementary Figure 30).  The sequencing pipeline also accurately quantitated both the 
number and relative abundance of barcode sequences present at unequal ratios when the least 





Table 1. Details of macaque infection and disease. 
 
3.4.2 Mapping M. tuberculosis infection dynamics in macaques.   
To define bacterial population dynamics in vivo, we infected 4 macaques (Table 1) with a goal 
inoculum of ~20 CFU of barcoded Erdman, where the delivery inoculum as determined by 
plating was 11 ± 5 CFU, recognizing there is uncertainty in this number created by plating and 
counting very low numbers of a very dilute sample.  We tracked temporal and spatial granuloma 
formation in vivo with serial 18[F]-FDG PET/CT for 15-20 weeks.  Lesions were identified, 
labeled, and characterized for size and PET avidity (SUV)39.  Using the final pre-necropsy 
PET/CT as a lesion map, we excised each individual lesion, plated their homogenates, scraped 
and sequenced the resulting colonies to decode bacterial founder identity.  By overlaying serial 
PET/CT scans with post-sequencing barcode identity, we were able to create a systematic history 
of productive—i.e. culture positive—lesion formation and dissemination in each animal (Figure 








4wk Gran Counts 
(PET/CT) 
Time to Nx 
(wks) 
Gross Pathology 






22 26 19 21 23,979 
17914 21 27 19 24 24,489 
18014 21 26 15 23 53,710 
18114 16 12 16 14 14,060  
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3.4.3 Concordance between estimated dose and number of bacteria that successfully 
establish infection.   
In other pathogens including Salmonella and HIV, barcode tracking has demonstrated that only a 
tiny fraction of the delivered organisms successfully establish infection143,144.  M. tuberculosis is 
thought to be a more efficient pathogen but the infective dose of M. tuberculosis has been 
difficult to define.  We compared the number of bacteria in the inoculum as estimated by plating 
with the number of unique barcodes identified in that animal to estimate the fraction of the 
inoculum that successfully established infection.  The number of bacteria in the inoculum closely 
matched the number of barcodes recovered from the animal.  These numbers also paralleled the 
number of granulomas identified by PET-CT at 4 weeks post infection (Table 1).  These data 
suggest that the early events of infection impose little to no bottleneck on the bacterial 
population and are consistent with the model that the infective dose of M. tuberculosis can be as 
low as one bacterium.  
3.4.4 A subset of granulomas disseminate to form new lesions. 
We then sought to define bacterial population dynamics through the first three months of 
infection, encompassing the window of dissemination that we previously identified between 3 
and 8 weeks of infection.  We have previously shown that at 3 weeks post infection, most 
granuloma harbor the progeny of a single founder132.  Here, we find that that the majority of 
granulomas even at later time points contain the progeny of a single bacterial founder, as most 
lesions (85%) had only one barcode sequence (Figure 6B).  Thus, we find little evidence of 
inter-lesional mixing of the bacterial population even after a period of dissemination.  Thoracic 
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lymph nodes often contained more than one barcode (75%), as expected for sites draining the 
lung.  However, only a minority of barcodes present in the lung were culturable from the lymph 
nodes, suggesting that not all granulomas productively disseminate to lymph nodes, at least at 
these later time points (Figure 6C-F).  
Barcode tracking defines two populations of granulomas: lesions containing bacteria that 
are derived from the same founder, which we interpret as the product of productive 
dissemination, and lesions harboring unique bacterial barcodes, which were “contained”—i.e. 
did not appear to have disseminated to form new culture positive lesions.  The pattern of 
dissemination varied across the four animals (Figure 6C-F).  In 3 macaques the majority of 
lesions were contained.  In one macaque, ID: 18014, ~80% of lesions were disseminated.  This 
appeared to reflect failure of containment at multiple sites as opposed to widespread 
dissemination from a single initial lesion.  On the whole, however, this analysis demonstrates 
that while nearly all bacteria in an infecting inoculum successfully establish a culture positive 
lesion, the majority do not contribute to further spread of infection.  Across all 4 animals, only a 
small fraction (8.75%) of granulomas were able to seed multiple (≥3) new granulomas in lung 





Figure 6. Contained and disseminated lesions from 15-20 week infected macaques.  
A.  Thoracic CT scan from animal 180-14, with barcode composition in lymph nodes (pie charts) and granulomas 
(bubbles).  Inset, 4 and 5 WPI (weeks post infection) with granulomas identifiable at those time points.  White arrow 
marks dissemination of ‘purple’ barcode from founder lesion at 4 WPI to new lesion at 5 WPI.  Red arrow marks 
dissemination of ‘olive’ barcode from founder lesion at 4 WPI to new lesion at 5 WPI.  B.  Quantification across all 
animals of number of unique barcode sequences found in granulomas and lymph nodes.  C-F.  Contained and 
disseminated barcode sequences in all recovered CFU+ lesions arrayed according to spatial distribution 
approximately from top to bottom of each lung lobe for the 4 macaques (macaque ID in top left of each graph).  
Blue shading reflects percentage of molecular counters out of total for a lesion for that barcode.  Numbered lesions 
were identified pre-necropsy by scan, lettered lesions were found during necropsy and often do not have 
corresponding XYZ coordinates.  Gastric aspirates in E were taken 13 days apart.  Barcodes are arbitrarily 
numbered.  RLL, right lower lobe; LLL, left lower lobe; ACC, accessory lung lobe; EP, extra-pulmonary; LN, 
lymph node; AIR, airway. 
3.4.5 Dissemination occurs primarily through local spread.  
We sought to better understand these patterns of dissemination by defining the spatial dynamics 
of bacterial spread.  Using 3-dimensional lesional coordinates from pre-necropsy PET/CT scans, 
we interrogated the spatial relationships between disseminated lesions containing the same 
barcode compared to the population of contained lesions (Supplemental Figure 31).  Lesions 
that share barcodes are closer together than the population of contained lesions (mean contained 
= 19.657mm, mean disseminated = 8.87mm) and are significantly different populations 
(D=0.615, p=2.82e-9) (Figure 7A).  Thus, most dissemination appears to result from local rather 
than hematogenous or lymphatic spread. 
Matching timing data from serial scans with barcode identity we also established the 
temporal dynamics of dissemination.  Consistent with previous findings39, there is substantial 
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dissemination within the first 6 weeks of infection.  After this window of early dissemination, 
there is a period of apparent quiescence and then a second wave of granuloma spread (Figure 
7B).   
 
Figure 7. Spatial and temporal characteristics of dissemination.  
A.  Density histogram of the Euclidean distance of each disseminated lesion (red) to contained (blue) lesions with 
the same barcode sequence across all animals.  Blue line is the Euclidean distance of all contained lesions to other 
lesions that do not contain the same barcode sequence.  Data is only reflective of lesions for which XYZ coordinates 
are known.  Dashed line is mean for each distribution, *; p < 0.05 by Welch’s t-test.  B.  Number of lung 
disseminating events across all animals at the indicated time points (WPI; weeks post infection).  Timing reflects 
definitive dissemination events matched with barcode and serial imaging. 
3.4.6 Disseminated lesions are larger than contained lesions.  
The variability in the patterns of dissemination was striking as even the animal allowing 
extensive dissemination was not identifiable by clinical course.  These animals were also not 
distinguished by their total bacterial burden at necropsy (Table 1), which were similar to the 
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average total CFU as compared to our historical data (N=18 cynomolgus macaques22,39 range = 0 
- 222,864; mean = 34,338; median = 6613).  
These data suggested that dissemination is driven by lesional as well as global features.  
We therefore sought to identify lesional characteristics that distinguish containing from 
disseminating lesions.  We compared the populations of T cells between these sets of lesions, but 
found minor differences in the frequency of cytokines produced by T cells following ex vivo 
stimulation (Supplemental Figure 32).  However, as dissemination and necropsy are separated 
by weeks-to-months, the quality of the immune response likely changed dramatically, and we 
cannot determine in this study T cell responses in granulomas at the time of dissemination. 
PET/CT imaging allows us to interrogate lesional biology over the course of infection, 
not simply at the time of necropsy. To begin to identify lesional features that correlate with fate, 
we screened disseminated and contained granulomas for differences in bacterial burden (Figure 
8A), cumulative bacterial load (CEQ) (Figure 8B), and bacterial killing (CFU/CEQ) (Figure 
8C) at the time of necropsy.  None of these parameters, determined by necessity only 15-20 
weeks post-infection, predicted the risk of dissemination.  Next, we evaluated 18[F]-FDG 
PET/CT characteristics including FDG avidity (SUVR) (Figure 8D) and size (Figure 8E) for 
each granuloma over the course of infection.  While SUV, a measure of metabolic uptake of 
18[F]-FDG and a proxy for inflammation, did not reveal any differences between the two lesion 
fates, granuloma size as measured by PET/CT early in infection (at 4-5wks) differentiated the 
two fates (p=0.0154); larger lesions early in infection were associated with a higher risk of 
dissemination and formation of new culture positive lesions.  
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Figure 8. Granuloma size early differentiates dissemination.  
A.  Bacterial burden (CFU) from granulomas obtained at necropsy (15-20 WPI) of contained (n=41) and 
disseminated (n=42) lesions from four barcoded macaques.  Data are reflective of lesions initiating dissemination as 
determined by temporal PET/CT analysis.  In instances where the precise founder is not known, all involved lesions 
were classified as disseminated. B.  Total bacterial load (live + dead; CEQ) of contained (n=20) and disseminating 
(n=28) lesions. C.  Bacterial killing determined by CFU/CEQ ratio for contained (n=20) and disseminating lesions 
(n=28).  D.  Granuloma FDG avidity (SUVR) and E. size (mm) of contained (n=36) and disseminating (n=30) 
lesions at 4-5 weeks post infection as assessed by PET/CT (*p=0.0154). Panels A-E: each symbol is a granuloma. 
Statistics for A-E: Mann Whitney test. 
3.5 PRELIMINARY DISSEMINATION IN EARLY INFECTION 
To assess this commitment to fate in early infection, we infected two additional macaques with 
14 CFU of barcoded Erdman and necropsied the animals between 4-5 weeks with PET/CT scans 
at 3 and 4 weeks.  As we did in the late-term macaques, we isolated individual lesions at 
necropsy using pre-necropsy scans and sequenced barcode identity from plated CFU.  Both 
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animals had fewer stable lesions than spreader lesions, with the majority of spread occurring 
between the lung and lymph nodes (Figure 9) rather than in formation of new lung granulomas. 
Differentiating disseminating and contained lesions in these early macaques not only confirmed 
our previous association between increased granuloma size and spread (p=0.0010) but also 
revealed a correlation between bacterial burden and spread (p=0.0130) (Figure 10). There was 
no correlation with FDG avidity (SUVR) in these time points between the two types of lesions 
(Figure 10). 
Figure 9. Early dissemination localizes to the lymph nodes. 
Left panel: barcode map, macaque ID: 17513; right panel: barcode map, macaque ID 15614. Images courtesy Vivian 
Leung, HSPH.   
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Figure 10. Granuloma size and bacterial burden differentiates dissemination in early infection.  
A. Bacterial burden (CFU) from granulomas obtained at necropsy (4-5 WPI) of contained (n=7) and disseminating 
(n=15) lesions from four barcoded macaques (*p=0.0262).  Data are reflective of lesions initiating dissemination as 
determined by temporal PET/CT analysis.  In instances where the precise founder is not known, all involved lesions 
were classified as disseminated.  B. Granuloma FDG avidity (SUVR) and C. size (mm) of contained (n=7) and 
disseminating (n=15) lesions at 4-5 weeks post infection as assessed by PET/CT (***p=0.0010). Panels A-C: each 
symbol is a granuloma. Statistics for A-C: Mann Whitney test. 
 
3.6 DISCUSSION 
To resolve the within-host bacterial population dynamics that contribute to the spectrum of M. 
tuberculosis infection, we generated a novel library of digitally barcoded M. tuberculosis and an 
associated Python pipeline for their identification and tracking in biological samples from 
macaques.  This barcode library and accompanying pipeline overcome significant hurdles 
inherent in this type of analysis.  By pairing information from serial PET/CT scanning with the 
sequence identities of bacteria from infected tissue, we have an unparalleled level of resolution 
of within-host infection dynamics at a lesional level.  Genome tagging has been used 
successfully to ask many questions about the population behavior of bacterial and viral 
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infections, but to date all of these strategies involved tracking of pools of known barcodes via 
exact sequencing matching to distinguish barcodes.  We have developed an approach to 
accurately identify and quantitate individuals pulled from a highly complex library where the 
sequence identifiers are not known a priori.  These tools allow us to confidently track the 
descendants of individual bacteria and the population as a whole. 
In this study, we sought to define constraints on the bacterial population from inoculation 
through the first five months post-infection.  Importantly, we found no evidence of significant 
impediments to the establishment of M. tuberculosis infection, in that the number of individual 
bacteria identified by digital barcode as well as the number of initial granulomas observed by 
PET/CT is similar to the estimated infectious dose.  While this study cannot assess all constraints 
on the bacterial population associated with transmission—especially those associated with 
aerosolization—it is consistent with the hypothesis that the natural infective dose of M. 
tuberculosis could be as low as a single organism145,146.  These data highlight the limited capacity 
of the earliest innate responses to prevent establishment of infection.   
Though the innate response does not appear to limit initial infection, it does appear to 
constrain early dissemination.  Indeed, we found evidence of significant constraints on 
dissemination, indicating that there is a bottleneck at the level of the granuloma.  In most 
animals, only a minority of granulomas seed a second, culture positive granuloma.  Previous 
work in the zebrafish model found that in contrast, dissemination was the rule and not the 
exception31.  
Our data suggest additional facets to the lesional variability that we have previously 
documented in terms of bacteriocidal capacity132.  We found that there is variability in the extent 
of dissemination that is an independent marker of disease course, distinct from total bacterial, 
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clinical, or radiographic measures of disease.  We demonstrated that granuloma size assessed by 
18[F]-FDG PET/CT in the first few weeks post-infection correlates with risk of dissemination.  
Size is not a proxy for higher numbers of bacteria in a granuloma (data not shown), which might 
be a simple explanation for the relationship with dissemination risk.  Instead, we speculate that 
size is an independent biologic feature and that physical expansion increases the bacterium’s 
access to avenues of spread.  Because most instances of productive dissemination that we 
identify are to sites less than 10mm away, it suggests that productive dissemination throughout 
the lung rarely occurs through the blood or lymph.  
To assess dissemination early, we infected two monkeys with barcoded M. tuberculosis 
and necropsied them at 4-5 weeks post infection.  Our preliminary findings suggested that 
dissemination is linked to granuloma size, as we saw in our longer-term monkeys, and, more 
interestingly, bacterial burden.  We hypothesize that prior to the onset of a robust adaptive 
response at around 4-6 weeks27,36, a proportion of granulomas support robust bacterial growth, 
enabling early spread, perhaps following inadequate innate containment and bacterial evasion.  
Recalling that the quantity of these early spreading events influences host outcome39, we propose 
that a critical axis exists between a lesion’s bacterial burden, physical capacity, and granuloma 
fate that relies on early bacterial control to minimize spread.  A more in-depth analysis of early 
and late dissemination is planned to better understand the basis for dissemination and how it may 
relate to early infection.  
Interestingly, spread to lymph nodes is also highly variable across infected 
macaques9,132,133.  Only 15% of barcodes were represented in the lymph nodes that were culture 
positive (2 macaques).  One current limitation of this work is that we are only able to confidently 
assess and sequence barcodes from live bacteria present at necropsy, i.e. those that grow on 
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plates, and not directly from tissue homogenate.  This is in part due to the paucity of bacterial 
genomic material in these samples, which makes the distinction between true and erroneous 
barcodes in the amplified library challenging.  Clearly, productive infection of the lymph node 
by every bacterial population in the animal is not required for the lymph node to sample and 
present the antigens from these populations. However, these data do raise questions about the 
extent of compartmentalization during M. tuberculosis infection, and how that might influence 
generation of adaptive immune responses. 
Questions like those of antigenic compartmentalization are only important if there are 
important functional differences between the bacteria in different sites within the host.  Our work 
to date has demonstrated that lesional bacterial populations are isolated from the earliest points in 
infection. Our previous studies of bacterial mutability35 have demonstrated that the rates of 
genetic mutation are too low to generate sufficient variation to account for observed differences 
in lesional course at these early time points during infection – though they don’t preclude genetic 
differentiation over longer time periods.  Furthermore, we cannot rule out the possibility of 
distinct patterns of transcriptional adaptation or epigenetic inheritance in these isolated bacterial 
populations that will be the subject of future studies.  One important lesson from these studies is 
the fact that the barcodes recovered from gastric and bronchoalveolar lavages, which are taken as 
proxies for the sputum in NHP, represent only a fraction of the bacterial barcodes (3.75%) 
present in the animal (Figure 6C & 6D).  These data are consistent with clinical studies 
demonstrating that organisms with different drug resistance patterns can be isolated from the 
sputum of individual patients and highlight the need to be cautious in interpreting the sputum 
bacteria as representative of the entire bacterial population within an individual147,148.  
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Previously we reported heterogeneity of granuloma features and bacterial control within a 
single infected animal and here we reveal another layer of heterogeneity and complexity between 
different granulomas.  Our findings reveal novel avenues of research to probe both host and 
bacterial factors that influence such disparate granuloma fates.  These new tools will allow 
further characterization into the dynamic local interactions of bacteria and host that ultimately 
govern both lesion fate and patient outcome.  Furthermore, the use of genome barcoding and 
tagging technologies has broad application, from development to cancer, and the new tools 
presented here will provide solutions to digitally tracking cells in a variety of fields.   
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4.0  PRIMARY INFECTION WITH MYCOBACTERIUM TUBERCULOSIS CONFERS 
PROTECTION TO SECONDARY INFECTION IN THE MACAQUE MODEL OF 
TUBERCULOSIS 
This chapter is adapted from the manuscript in preparation: 
Anthony M. Cadena, Constance J. Martin, Vivian W. Leung, Philana Ling Lin, Pauline 
Maiello, Nathan Hicks, Michael R. Chase, Sarah M. Fortune# & JoAnne L. Flynn#, Primary 
infection with Mycobacterium tuberculosis confers protection to secondary infection in the 
macaque model of tuberculosis, manuscript in preparation, 2017. #Corresponding authors. 
4.1 INTRODUCTION 
It is increasingly recognized that individuals are repeatedly infected with M. tuberculosis.  
Estimates place reinfection TB as high as >50% in individuals that have successfully completed 
treatment for an initial episode of TB149-152 emphasizing its prevalence and highlighting the 
discordance between a previous infection, clearance, and renewed susceptibility152,153.  In 
addition, recent studies have indicated that cases of multiple isolate infection (mixed infection) 
can occur in around 2-18% of active TB patients151,152 and that such cases can result in disparate 
drug sensitivities complicating disease management150,151,154.  Further confounding these 
epidemiological estimates is the unknown burden of reinfection among individuals with latent 
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TB infection (LTBI)155.  How all these previous infections with M. tuberculosis influence 
subsequent infection is poorly understood and whether such instances confer protection or 
exacerbate pathology remains a key question in TB.  
Early observations among entering nursing students in the 1920s suggested that those 
students that were initially PPD negative were at higher risk to develop active TB relative to 
those that entered with PPD positivity, and thus implicate a level of protection in LTBI.  
Subsequent studies have attempted to characterize the level of protection but have had variable 
results13,156,157.  A more recent comprehensive survey of the epidemiology literature by Andrews 
et al suggests that latent TB infection in humans may reduce the risk of progression to active TB 
after re-exposure by as much as 79% compared to uninfected individuals13, however these 
epidemiological studies are limited in that the variables are notoriously difficult to control.  
Appropriately evaluating the effect of LTBI in this context is crucial as drug treatment within 
this group, which occurs in some regions of the world10,158, may alter or subvert this apparent 
protection.  A recent LTBI study in South African gold miners by Churchyard et al demonstrated 
diminished protection following termination of preventive therapy implicating a potential 
requirement for an ongoing infection for protection159.  In an experimental setting with drug 
treatment, a mouse model of reinfection using the virulent W-Beijing M. tuberculosis strain 
HN878 found that mice were transiently resistant to reinfection in this animal model160.   
Additional study is needed to adequately determine whether previous exposure or infection with 
M. tuberculosis provides protection against establishment of a second infection, which is very 
difficult to assess in humans unless there is progression to disease, as well as against disease. 
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4.2 METHODS AND MATERIALS 
4.2.1 Macaque infections, PET/CT imaging, and tissue excision 
Fourteen adult cynomolgus macaques (Macacca fasicularis) were obtained from Valley 
Biosystems (Sacramento, California) and screened for M. tuberculosis and other comorbidities 
during a month-long quarantine.  Each macaque had a baseline blood count and chemical profile 
and was housed according to the standards listed in the Animal Welfare Act and the Guide for 
the Care and Use of Laboratory Animals.  The animals were separated into two cohorts: 8 
macaques were assigned to reinfection and 6 were assigned to 4-week only controls.  All animals 
were infected with barcoded strain Erdman M. tuberculosis via bronchoscopic instillation as 
previously published49,125.  The infection schema is provided below in Figure 11 with the 4-
week only animals receiving only barcoded library B in a series of matched infections with their 
reinfection counterparts.  All animals received an inoculum of >15 CFU (determined by plating a 
sample of the inoculum and counting CFU after 3 weeks) with the precise details listed in Table 
2.  The animals were further subdivided such that 4 reinfection animals were directly paired with 
2, 4-week only control animals; 2 additional 4-week only animals were infected separately to 
supplement early infection data (Table 2).  Each macaque was followed with serial 2-deoxy-2-
[18F]-fluoro-D-glucose ([18F]-FDG) PET/CT imaging as previously described39,109,132 to identify 
and track lesion formation and progression over time.  As before, lesions were individually 
characterized by their date of establishment (scan date), size (mm), and relative metabolic 
activity as a proxy for inflammation ([18F]-FDG standard uptake normalized to muscle [SUVR]).  
Lesions > 1mm can be discerned by our PET/CT imaging analysis. To avoid barcode cross-
contamination, individual granulomas were separately excised and processed using the animal’s 
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prenecropsy scan as a guide for identity and location.  All lesions observed post second infection 
in the reinfection cohort were initially labeled as secondary lesions pending library qTag 
verification.   
4.2.2 Isolation and preparation of bacteria from tissue samples 
Following removal at necropsy, each lesion was homogenized and plated for bacterial burden on 
7H11 agar supplemented with oleic albumin dextrose catalase (OADC).  A small portion of 
homogenate was frozen for qTag sequencing as well as chromosomal equivalent (CEQ) analysis.  
Genomic DNA was extracted using  
4.2.3 T cell flow cytometry profiling and intracellular cytokine staining 
At necropsy, granulomas, lung tissues, and thoracic lymph nodes were processed into single cell 
suspensions with sterile PBS.  A portion of these suspensions were used for T cell profiling and 
characterization.  T cells were initially stained for viability using the LIVE/DEAD Fixable Blue 
Dead Cell Stain Kit (ThermoFisher Scientific) and then stained for T cell-specific markers using 
the anti-human CD3 (clone SP34-2, BD Pharmigen), anti-human CD4 (clone L200, BD 
Biosciences), and anti-human CD8 (clone RPA-T8, BD Biosciences) antibodies in a standard 
FACs buffer.  
 For intracellular cytokine staining, tissue suspensions were stimulated with M. 
tuberculosis CFP10 and ESAT6 (BEI Resources, Manassas, VA) and Brefeldin A (GolgiPlug, 
BD Biosciences) in RPMI (Lonza, Walkersville, MD) supplemented with 1% L-glutamine and 
1% HEPES (Sigma, St Louis, MO) for 3.5 hours.  The final concentration of the M. tuberculosis 
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specific peptides was 2.5µg/mL.  Following surface staining as detailed above, the cells were 
fixed and permeablized (BD Cytofix/Cytoperm) and washed with BD Perm/Wash buffer (BD 
Biosciences).  Incubations were all performed according to manufacturer recommendations.  
Cells were then stained with the following intracellular cytokines: anti-human IFNγ (clone B27, 
BD Biosciences), anti-human TNFα (clone Mab11, eBiosciences), anti-human IL-2 (clone MQ1-
17H12, BD Biosciences), IL-6 (clone MQ2-6A3, BD Biosciences), anti-human IL-10 (clone 
JES3-9D7, eBiosciences), and anti-human IL-17A (clone eBio64CAP17, eBiosciences). 
Flow cytometry was preformed on a LSR II (BD) and analyzed using FlowJo Software 
v.9.8 (Treestar Inc., Ashland, OR).  Size (FSC) and granularity (SSC) were used to isolate the 
lymphocyte population at the cytometer. All cytokine data presented are gated on CD3+ T cells.  
4.2.4 Statistical analysis 
Statistical analysis was performed in Graphpad Prism, JMP and R, significance was defined as p 
< 0.05.   
4.3 APPROACH 
To evaluate the contribution of an ongoing infection on subsequent infection in TB, 14 macaques 
were separated into two sets, a reinfection set and a matched 4 week only set (Table 2).  The 8 
animals in the reinfection set had a primary infection for 16 weeks followed by a secondary 
infection for 4 weeks; each infection was carried out with a separate barcoded library.  The 6 
animals in the four week-only controls animals received only the second barcoded library 
 64 
(Figure 11).  The infections of the second group of monkeys were performed in parallel with the 
second infection of the reinfection cohort, except for 2, 4 week only animals that formed a third 
infection group used to supplement our early infection data (Table 2).  This study design was 
critical to compare reinfection in a setting controlling for dose and inoculum variation such that 4 
week secondary granulomas could be directly evaluated against 4 week primary granulomas, a 
critical time point where granuloma bacterial burden is highest36, and, thus, a potential phenotype 
most evident.  As of the date of this writing, primary and secondary granulomas were 
distinguished using [18F]-FDG PET/CT imaging39,109,132, pending library qTag validation through 
sequencing.  Consequently, any new lesions that were observed after the second infection were 
termed “secondary lesions” resulting in an unbiased but perhaps overestimated contribution of 
granulomas arising from the second infection in some animals.  We expect that sequence 
analysis will eventually show that some lesions were actually due to spread from the primary 
infection in some animals.  
 
Figure 11. Schematic of Reinfection Study Design. 
14 animals were separated into reinfection and 4wk only controls with 8 and 6 macaques, respectively.  Animals in 
the first group were infected with two successive libraries of barcoded M. tuberculosis (A and B) with a 16 week 
interval between them.  Animals in the second, 4 week only control group were infected with only library B in a 




Table 2. Parameters of macaque infections, imaging, and disease.  
4.4  RESULTS 
4.4.1 Primary infection protects against secondary infection by limiting granuloma 
formation and reducing granuloma bacterial burden 
Using [18F]-FDG PET/CT to count the numbers of new, secondary lesions (i.e. those that only 
become apparent subsequent to infection with Library B), we observed a trend towards an 
overall reduction in the numbers of new granulomas formed from the second M. tuberculosis 










Total CFU PET/CT Scans (wks) 
18915 




6±1 4 7 318,039 2, 3 
19015 6±1 4 17 1,738,747 2, 4 
19915 5±1 4 19 564,310 2, 4 
20015 5±1 5 11 104,809 3, 5 


















2°: Library B 2.0 
Barcoded Mtb 
Erdman 
1° = 5±1 
2° = 5±1 20 23 37,756 4, 6, 8, 12, 15, 18, 20 
19215 1° = 5±1 2° = 5±1 20 22 6719 4, 6, 8, 12, 15, 18, 20 
19315 1° = 5±1 2° = 5±1 21 12 12,196 4, 6, 8, 12, 15, 18, 21 
19415 1° = 5±1 2° = 5±1 21 22 4,334 4, 7, 8, 13, 15, 18, 21 
19515 1° = 8±1 2° = 10±1 20 38 361,420 4, 8, 12, 16, 20 
19615 1° = 8±1 2° = 10±1 20 57 122,872 4, 8, 12, 16, 20 
19715 1° = 8±1 2° = 10±1 21 34 10,600 4, 6, 8, 12, 16, 19, 21 
19815 1° = 8±1 2° = 10±1 21 28 3,331 5, 6, 8, 13, 16, 19, 21 
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group (Figure 12B), the granuloma reduction becomes more apparent with the most surprising 
finding that four macaques in the reinfection set exhibit nearly complete to complete protection 
(ID: 19315, 19415, 19715 & 19815) against establishment of new granulomas.  In the first 
infection group, the estimated CFU for the second library was 5±1, which is close to the 
threshold of infection despite a conservative, calculated error rate.  A more robust reduction was 
appreciated in the second infection group where the estimated CFU for the second library was 
10±1.  Here, in spite of an infection dose of 10, we have two macaques that have two and zero 
new lesions, respectively (Figure 12B).  The other two monkeys in that group have higher 
secondary granuloma counts than their 4 week only counterparts, which is likely due, in part, to 
an actively disseminating primary infection resulting in overestimation by [18F]-FDG PET/CT 
and await qTag verification for definitive library placement.  To our knowledge, this is the first 
reported instance of complete protection against the establishment of infection observed in a 
macaque model of tuberculosis, including in vaccine studies.  
 In addition to assessing the numbers of granulomas formed following a second infection 
in the context of reinfection, we interrogated the overall bacterial burden of the secondary 
granulomas that were able to successfully establish at 4 weeks post second infection.  We found 
that bacterial load in these secondary granulomas were several orders of magnitude lower than 
age-matched primary granulomas, with a significant number having sterilized altogether (53% 
vs. 15%) (Figure 13A &13B). Collectively, our two observations that primary infection limits 
both the establishment and bacterial growth of secondary granulomas implicates the presence of 




Figure 12. Primary infection limits secondary granuloma development.  
A. Granuloma counts of age-matched primary (n=6 animals) and secondary (n=8) lesions (4-5weeks post infection) 
(p=0.2153); each symbol is a monkey.  B. 4 week granuloma counts separated by monkey and infection group.  In 
each group, the animals received the same dose of the second library (M. tuberculosis Erdman Library B); group 1 = 
5±1 CFU, group 2 = 10±1 CFU, and group 3 = 6±1 CFU.  The last group only had 2, 4 week only control animals.   
 
 
Figure 13. Secondary granulomas have significantly fewer bacteria than primary granulomas.  
A. CFU of 4 week, age-matched primary (n=33) and secondary (n=47) granulomas (****p<0.0001), each symbol is 
a granuloma.  B. 4 week granuloma CFU separated by monkey and infection group, as above in Figure 12, each 
symbol is a granuloma and all are from barcoded M. tuberculosis library B.  
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4.4.2 Secondary lesions have more robust cytokine expression than age-matched primary 
lesions 
To begin to dissect a possible mechanism driving the protection observed in secondary infection, 
we examined age-matched primary and secondary lesions using ex vivo stimulated, intracellular 
cytokine staining.  We found that a higher frequency of CD3+ T cells in the 4 week secondary 
granulomas produced IL-2, IL-6, and IL-10, and a trend towards higher production for IL-17A 
and TNFα (Figure 14). Only IFN-γ did not appear to be upregulated relative to 4 week primary 
granulomas.  
 
Figure 14. T cells in secondary granulomas produce greater amounts of pro- and anti-inflammatory 
cytokines.  
A-F. CD3+ T cell cytokine expression for IFN-γ, IL-2, IL-6, IL-10, IL-17A, and TNFα, respectively, between 4 
week primary (n=27) and 4 week secondary (n=10) granulomas (*p>0.05 and **p>0.01).  All plots use a 30 T cell 
minimum. Each symbol is a granuloma.  
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4.5 DISCUSSION 
In this study, we addressed reinfection in the macaque model of TB by directly comparing 
infection establishment, bacterial burden, and granuloma immune profiles in a paired set of 
macaque cohorts.  Our data support enhanced protection against early (4 week) secondary 
infection following a primary infection.  Importantly, this is a critical time point in infection as 
clearance of M. tuberculosis is least effective, bacterial dissemination is prominent, and bacterial 
load is highest7,27,36.  Most surprisingly, we report the novel finding of complete protection 
against the establishment of secondary infection in several macaques (Figure 12) suggestive of 
highly effective mycobacterial immunity in the lung and airway.  Moreover, in the secondary 
granulomas that were able to form, we report >1000 fold bacterial killing further indicative of a 
potent, antibacterial state in these granulomas, with the median bacterial burden at 0 (Figure 13).  
The finding that a large portion of 4 week granulomas was sterile is surprising as our previous 
data has shown that granuloma bacterial load in primary infection is greatest in the first several 
weeks of infection36, most likely due to the delay in adaptive immunity27.  We hypothesized that 
the enhanced killing in the reinfected animals was a result of the local lung immunity generated 
by a primary infection and our initial T cell cytokine profiling of the 4 week, secondary 
granulomas revealed significant upregulation of both pro- and anti-inflammatory cytokines 
(Figure 14).  We speculate that the subsequent, pan-hyperresponsive cytokine state promoted a 
balanced immune microenvironment in which both antibacterial responses and 
immunopathology were maintained appropriately30; two immune components that have 
previously been shown to best correlate with granuloma sterility133.  Subsequent studies in 
reinfection will carefully probe the immune profiles and functionality of both innate and adaptive 
factors in the lung and airway to better understand the immune signatures providing this 
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protection.  Further study is required to determine the durability of protection against M. 
tuberculosis seen here as well as the apparent necessity for live M. tuberculosis to elicit the 
appropriate immunity, as the current BCG vaccine does not engender such protection2,3.  
Ultimately, our work in reinfection provides exciting clues for novel immunological biomarkers 
of protection that will inform more effective vaccine development6,161.  
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5.0  THE INFLUENCE OF M. TUBERCULOSIS ON THE LUNG MICROBIOME IN 
THE MACAQUE MODEL OF TUBERCULOSIS 
This chapter is partially adapted from the accepted NIH grant RO3 AI122067 (Flynn JL, Lin PL, 
and Ghedin E, 2015) and represents an ongoing study probing the relationship of the lung 
microbiome and M. tuberculosis infection in the macaque model of tuberculosis that I initiated. 
 
5.1 INTRODUCTION AND INNOVATION 
Microbial dysbiosis is increasingly being recognized as a significant factor influencing human 
disease in a variety of contexts spanning allergy, autoimmunity, cancer, and infectious disease162. 
The gut microbiome, in particular, has had the greatest amount of literature linking the immune 
system and an organ’s microbiome163 but it is increasingly becoming clear that other human 
immune surfaces and interfaces including the lung are shaped by host-microbe interactions164,165. 
Specific human studies linking lung microbiome changes and bacterial infections are limited, but 
earlier work in Pseudomonas aeruginosa166 has identified an association between airway 
microbial loss and pathogen colonization suggesting that microbial diversity can influence 
pathogen selection and disease at this site.    
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Here we explored the effects of M. tuberculosis infection on the lung microbiota over the 
first several months of infection in a macaque model of TB, using serial bronchoalveolar lavage 
(BAL) samples obtained from animals funded on other studies. This initial exploration of the  
dynamic changes in microbiota in response to M. tuberculosis infection, and preliminary 
correlations with outcome measures of infection, will provide novel data and set the stage for 
more focused future investigations of the influence of lung microbiota on M. tuberculosis 
infection. 
In this study, we coupled our cynomolgus macaque model of TB125 with the unique 
ability to serially sample the airways of animals throughout the course of infection.  We 
exploited the technologies that we have developed with respect to PET/CT imaging, 
immunologic analyses, clinical assessments, prediction of outcome, and genomic sequencing 
analyses39,49,53,167-170 to determine the duration of effect of M. tuberculosis infection on the lung 
microbiome. This is the first targeted exploration of the lung microbiome in a model of TB that 
replicates human infection outcomes and pathology.  
5.1.1 Tuberculosis and the microbiome 
Almost nothing is known about the interaction of the lung microbiome and M. tuberculosis.  M. 
tuberculosis causes a chronic lung infection as primary disease can take up to 2 years to be 
clinically diagnosed and humans with latent TB can remain infected for their lifetime. 
Reactivation of clinically latent infection can occur years to decades after initial infection. Cross-
sectional human studies examining the interaction of M. tuberculosis infection and lung 
microbiota (measured by sputum) have been limited but suggest that TB patients have altered 
diversity in their sputum microbiota compared to uninfected humans171,172. The distribution of 
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some genera (Stenotrophomonas and Phenylobacterium) was unique to TB patients172. Certain 
patterns of microbiota (e.g., presence of Pseudomonas spp.) were observed in patients with 
recurrent TB and treatment failure suggesting that the lung microbiota interacts with both host 
and pathogen173. Specifically, alterations in Treponema and Atopobium were associated with 
recurrent TB suggesting that an altered “normal” microbiome is associated with ongoing 
susceptibility to TB173. Studies examining the microbiota of the oropharynx between health 
controls and TB patients showed differences in diversity and abundance of particular organisms 
although no differences in major phyla were observed174.  Distinct changes in the gut 
microbiome were observed after experimental M. tuberculosis infection in a mouse model175, 
although the effects of these changes on course of infection are not clear. Perry et al showed that 
seroprevalence of H. pylori in humans was associated with a decreased risk of progression to TB 
disease and this pattern was recapitulated in our cynomologus macaque model of M. tuberculosis 
infection176. 
5.2 METHODS AND MATERIALS 
5.2.1 Microbiome sample collection and M. tuberculosis infections  
To sample the oral flora, we first obtained a 5mL rinse of the cheek pouches by administering 
5ml of PBS by syringe and then recovering as much liquid as we could.  We followed the oral 
cavity washing with a 5mL saline wash of the sterilized bronchoscope to detect any residual 
DNA within the scope.  To minimize subsequent lower airway broncheoalveolar lavage (BAL) 
sampling, we swabbed each animal’s mouth with an antiseptic agent (chlorohexane). A 7mL 
 74 
saline lavage of the uninfected lower lung (often left lung) was performed, followed by 
sterilization of the scope with antiseptic solution (Cidex, Civco Medical Solutions) before 
sampling the opposite infected lung. From these lavages, we collected approximately 3-5mL 
from each lobe and immediately aliquoted into 2-4.5mL cryovials and froze the vials at -80°C.  
Thus, from each monkey at each time point, we had 4 samples (mouth, scope, right lower lobe, 
left lower lobe) (Figure 15).  Our serial sampling was done at pre-infection (0), 1, 4 and 5-
months post-infection (several macaques had sampling only out to 4 months due to the onset of 
drug treatment).  Monkeys were infected with <25 CFU M. tuberculosis strain Erdman via 
bronchoscopic instillation into the right lower lung, as we have previously described42,49. The 
animals for this project are from separately funded studies of Dr. Flynn and Dr. Lin, and are un-
manipulated except for M. tuberculosis infection. Samples are analyzed using target gene 
sequencing of the V4 hypervariable region of 16S rRNA for bacteria169 (see below).  To date, we 
have obtained serial samples from 26 M. tuberculosis infected cynomolgus macaques and a 
further 10 will be sampled in the following year.  
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Figure 15. Schematic of macaque airway sampling. 
Ongoing clinical assessments (e.g., cough, appetite or weight loss), erythrocyte 
sedimentation rate (ESR, marker of systemic inflammation) and gastric aspirate and BAL for M. 
tuberculosis growth were performed to obtain clinical outcome measures as described42,49. More 
importantly, PET/CT imaging of lung disease in all of these animals will be obtained over the 
course of infection, including at the 4 and 5-month time points to assess disease progression. As 
noted above, we have identified several parameters of PET/CT change that are correlated with 
extent of disease. 
5.2.2 DNA extraction from BAL samples 
To avoid potential contamination, all DNA extractions are performed in a dedicated biosafety 
level 3 cabinet that is first exposed to a UV light source for 15 minutes. Samples were prepared 
in batches by monkey, where each sample is thawed and centrifuged, and the PowerSoil® DNA 
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extraction kit (MO BIO Laboratories, Inc.), which includes a bead-beating step, is used to extract 
the DNA. 
5.2.3 Analysis of microbial community structures 
Dr. Elodie Ghedin, an expert in genomic characteristics of the microbiome as they relate to lung 
infection, and her laboratory preformed the taxonomic analysis of samples. The 16S amplicon 
sequence data from the samples were processed using the following pipeline: first, we used the 
Mothur pipeline177,178 modified for the MiSeq platform, which includes removal of low quality 
reads, chimeras (UCHIME), non-mate-paired reads and merging of paired-end reads179. 
Taxonomic assignments of the sequences were made using the RDP (Ribosomal Database 
Project) classifier180, which classifies sequences to the genus level.  Second, we utilized 
taxonomy-independent analyses through the generation of Operational Taxonomic Units 
(OTUs), which provide classifications at approximately the species level by clustering sequences 
based on nucleotide identities of ≥97% using the UCLUST program 181 Assignments of 
taxonomy were further refined through phylogenetic methods including using PyNAST 182 to 
generate an alignment for each cluster from which a phylogenetic tree was built using the 
FastTree approximately-maximal-likelihood method183. Third, we used the taxonomic and OTU-
based profiles in a series of ordination, clustering, and community structure (measuring richness 
and evenness) analyses designed to compare and identify significant shifts in 16S rRNA profiles 
between samples and for further statistical analyses (see Statistical Analyses). Finally, we 
determined the stability in the structure of the microbiome over time using the ordination, 
clustering and diversity analyses and comparing data across time points. 
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5.2.4 Neutral Model Analysis  
The data from the oral wash and the bronchoscope control were used to determine which 
microbe (identified in the taxonomic analysis described above) was a true resident of the lung 
rather than a microbe from the mouth. To do this, we applied the neutral model of community 
ecology 169,184. This model examines whether distribution of organisms in the lung results from 
dispersal from the mouth or from active environmental selection in the lungs. This analysis 
allowed us to determine true residents of the lungs and how their representation varies over time 
(see Statistical Analyses). 
5.2.5 Statistical Analyses 
Whole community structure changes were analyzed using Adonis, a multivariate ANOVA based 
on dissimilarities, available in QIIME185. Individual OTUs that differ between infected and 
uninfected lobes were identified with repeated measures ANOVA. To examine the relationship 
of microbial communities to both systemic marker of inflammation (ESR) and lung TB-specific 
inflammation by PET/CT, we will use a random intercept model, or linear mixed model, with 
autoregressive correlation structure; a LASSO penalty will be added to this regression to account 
for the large number of potential fixed effects (OTUs). On categorical variables, the linear mixed 
model will be replaced with a logistic mixed model with the same autoregressive correlation 
structure and penalty parameters. To test the shifts in abundance for specific taxa due to M. 
tuberculosis infection, we also employed smoothing spline ANOVA (SSANOVA) methods 
(http://cbcb.umd.edu/software/metagenomeSeq). We have previously used these methods in a 
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separate study on the progression of differential abundance of specific oral microbial taxa during 
the course of a SHIV infection186. 
5.3 PRELIMINARY RESULTS 
Lung microbiome analyses have been performed on the first cohort of 10 macaques with a total 
of 162 samples (Table 3). The second set of 16 macaques is in progress.  Sequencing and 
analysis was performed for all oral wash and BAL samples using the bronchoscope and reagent 
controls for appropriate thresholding. The data below is representative of the first set of 10 
animals.  Infection status of each lung lobe is determined by PET/CT at each sampling time 
point36,39,109 allowing for direct comparisons of infected and uninfected lobes over time.   
 
Table 3. Lung Microbiome Samples 
 







1 10 70 36 36 20 162 
2 16 114 58 58 32 262 
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5.3.1 The oral microbiome is distinct from the lung microbiome  
Using principle component analysis (PCA), comparison of OTUs between the oral wash and 
BAL reveals that the oral cavity clusters separately from the lung lobes, irrespective of time 
point post infection (Figure 16).  While the infected and uninfected lobes (red and blue, 
respectively) are spread along the first component (axis 1), the oral samples are tightly clustered 
with very little spread indicating that the microbial composition of this compartment is distinct 
from the lower airway.   
 
Figure 16. Principle component analysis reveals discrete microbial landscapes between the oral and lung 
environment.   
Figure courtesy Elodie Ghedin, NYU.  
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5.3.2 The lung microbial community changes over time following infection 
To look for differences over time following M tuberculosis infection, we compared the alpha-
diversity of the OTUs from infected and uninfected lobes (determined by PET/CT) from all 
macaque at each time point.  We find that at 4 months post infection, there is a trend towards 
greater microbial diversity in the infected lobe (p=0.08) (Figure 17).  This shift appears to be 
transient as the diversity then begins to decrease in the following month.   
 
Figure 17. Lung microbial diversity shifts over time with M. tuberculosis infection.  
Alpha-level diversity of BAL samples throughout infection between uninfected (blue) and infected (red) lobes 
(+p=0.08). Figure courtesy Elodie Ghedin, NYU.  
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To better understand the specific microbial communities contributing to the change at 4 
months, we analyzed the data with the linear discriminate analysis (LDA) effect size (LEfSe) 
method187.  This approach helps to determine features responsible for the differences found 
between class comparisons on a metagenomic scale.  Using this method, we determined that in 
this first macaque set, the bacterial genera Fusobacterium, Neisseria, and Aggregatibacter were 
associated with M. tuberculosis in the infected lobe and Burkholderia in the uninfected lobe 
(Table 4).  Subsequent time-dependent Smoothing Spline ANOVA (SSANOVA) analyses 
validated all of the associations except for Neisseria (Table 4).  
 







5.3.3 The oral and lung microbiome are highly variable across macaques  
By separating out the ten bacterial genera with the highest relative abundance of OTUs in the 
infected lobe for each macaque during M. tuberculosis infection, we see that there is great 
diversity across animals (Figure 18).  Several macaques display little change in the lung 





Fusobacterium Infected 4.363 0.003 0.010 
Neisseria Infected 4.221 0.015 - 
Aggregatibacter Infected 4.113 0.004 0.019 
Burkholderia Uninfected 4.336 0.0003 0.010 
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microbiome following infection, whereas others display a high degree of variability, both with 
respect to magnitude and duration.   
 
Figure 18. There is a high degree of variability across macaques during infection.   
The relative abundance of taxa of the infected lobe for each monkey (ID across top) over the course of M. 
tuberculosis infection. (B=pre-infection, 1=1 month post infection, 4=4 months post infection, and 5=5 months post 
infection.) Figure courtesy Elodie Ghedin, NYU.  
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5.3.4 Pulmonary inflammation is highly variable across macaques 
To begin to relate pulmonary inflammation with the changes in the lung microbiota, we 
quantified lung inflammation, as measured by [18F]-FDG avidity (Total PET hot), in each 
macaque at 1, 4, and 5 months post M. tuberculosis infection (Figure 19).  Each time point 
coincides with the BAL lung microbiome sampling that was done above. There is a wide range 
of lung inflammation observed in these animals.  Several macaques exhibited large changes in 
total PET hot at 4 months whereas others animals have relatively little pulmonary inflammation 
throughout infection. A more precise analysis will be performed on each macaque in which each 





Figure 19. Total pulmonary lung inflammation in infected macaques.  
Using [18F]-FDG avidity (total PET hot), we assessed lung inflammation in all macaques (n=26) over the course of 
M. tuberculosis infection.  
 
5.4 DISCUSSION/FUTURE DIRECTIONS 
This primary aim of this study is to determine whether M. tuberculosis influences the lung 
microbiome following infection.  Analysis of the first cohort of ten macaques reveals that M. 
tuberculosis can induce changes in the lung microbiome of infected macaques, but that the 
alteration is variable across macaques.  Importantly, our study strategy is designed to compare 
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infected lobes from uninfected lobes within the same macaque across infection to minimize the 
masking effect of animal-to-animal variability.  We find that the changes are specific to the 
infected lobe, relative to the opposite, uninfected lobe, and greatest in the 4th month post 
infection (Figure 17).  We subsequently preformed metagenomic LDA effect size analyses 
(LEfSe) to better discern the specific microbial genera most likely driving the difference in lobe 
status and discovered that Fusibacterium, Neisseria, and Aggregatibacter are associated with M. 
tuberculosis (Table 4).  Interestingly, these microbes are normally associated with the 
oropharynx188 and may suggest opportunistic, migratory colonization following M. tuberculosis 
infection that stems from inflammatory dysbiosis in the lung129,188.  Dickson et al present a 
model of airway dysbiosis and inflammation in which an insult (infection, allergy, or 
environmental agent) triggers an inflammatory state that perpetuates a cycle of microbial 
alteration and respiratory inflammation driven by changes in growth conditions and distorted 
pulmonary architecture129 (Figure 20).  While the functional significance of the increase in 
several oropharynx species is not known, it implies that there may be less separation between the 
upper and lower respiratory tract during infection, and, when coupled with lung inflammation, 
may drive differential host responses in infection.  Going forward, we will finalize our full data 
set of 26 animals and rerun all analyses to validate and finalize our observations and conclusions.  
Ultimately, we aim to relate the microbiome changes to pulmonary inflammation using our serial 
FDG PET/CT imaging39,109.  We have quantified the total lung inflammation in the 26 animals 
(Figure 19) and observed a wide range of inflammation with several macaques exhibiting an 
increase in inflammation at 4 months, others had no changes in inflammation at all; this 
heterogeneity matches the range of infection outcomes that we see in this animal model49,125 and 
in humans.  Interestingly, the total PET hot increases at 4 months coincide with the increased 
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microbial diversity observed above (Figure 17).  This relationship will be further examined on a 
lobe-by-lobe basis for each macaque.  We will also look for evidence suggesting that the degree 
of inflammation influences the duration and magnitude of lung microbiome alteration.  Finally, 
we will generate a microbial interaction network to visualize how the microbes influence each 
other over the course of M. tuberculosis infection. A better appreciation of the interactome 
between host immunity, lung microbiota, and pathogen is important as it presents a fresh domain 
to study that likely contributes to host heterogeneity and a new potential for therapy.  It is 
intriguing to speculate that certain microbial species could be utilized in tandem with 
chemotherapy or vaccination to minimize inflammation or enhance/polarize specific immune 
cells for better bacterial killing.  
 
Figure 20. Cycle of lung microbiome dysbiosis and airway inflammation.  
A pulmonary insult initiates localized inflammation that modifies airway function and architecture leading to altered 
growth conditions that in turn promotes microbe dysbiosis through various selective pressures. 
 87 
5.5 ACKNOWLEDGEMENTS   
We thank the members, laboratory technicians and veterinary staff of the Flynn and Ghedin 
laboratories for their technical expertise and assistance with animal care, sample processing, 
bioninformatics analysis, and study design.  This work was made possible by support from the 
National Institutes of Health, R03 AI122067 (JLF, PLL & EG) and T32 AI089443 (AMC).    
 
 88 
6.0  IMPLICATIONS OF DISSERTATION: SIGNIFICANCE, CONCLUSIONS AND 
FUTURE STUDIES 
In this dissertation, we have coupled our well characterized macaque model of tuberculosis, 
which appropriately captures and recapitulates the full spectrum of human infection and 
disease42,49,109,126,189, with novel molecular, imaging, and bioinformatics tools to address several 
important questions in early M. tuberculosis infection.  Early events in this bacterial infection are 
critical junctures during which key components of the immune system are poised to either 
interact favorably to promote containment or interact poorly and allow for early dissemination.  
These initial interactions influence host outcome27,39 and likely contribute to the overall 
heterogeneity observed in human infection.  In this body of work, we have specifically tackled 
questions involving dissemination, reinfection, and the lung microbiome.  Each of these three 
domains are uniquely tied to early infection and their exploration has provided new insight into 
how to exploit the earliest exchange between bacterium and host in favor of man.  
6.1 SIGNIFICANCE 
In 2015, TB overtook AIDS as the leading infectious disease killer worldwide with an estimated 
1.4 million deaths, and a further 0.4 million deaths among human immunodeficiency virus-
positive (HIV+) individuals1.  Overall incidence for the same year was an estimated 10.4 million 
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cases, of which there was approximately 580,000 cases of drug-resistant tuberculosis1.  These 
numbers persist in spite of widespread infant vaccination with M. bovis Bacille-Calmette et 
Guerin (BCG) in endemic areas and inexpensive and effective antibiotic treatment2,190,191.  This 
is, in part, due to poor patient compliance and poor access to health care, which limits the 
efficacy of chemotherapy despite an estimated 90-95% cure rate in TB treatment control 
programs in drug-sensitive cases2,158.  Moreover, the BCG vaccine is reputed to protect against 
the worst forms of disseminated TB in children but has a highly variable rate of protection in 
adults likely stemming from multiple factors including differences in geographic location, route, 
substrain, and the local, lung environment191; newer, more reliable and effective vaccines are 
needed.   
6.2 CHAPTER CONCLUSIONS AND FUTURE STUDIES 
6.2.1 Barcoded M. tuberculosis reveals a bottleneck of secondary dissemination that is 
predicted by early granuloma size.  
To probe dissemination and track early bacterial dynamics, we generated a novel M. tuberculosis 
barcoding system with an associated Python pipeline that has given us unparalleled ability to 
track the fate of individual bacilli in infected macaques.  Moreover, when paired with our serial 
[18F]-FDG PET/CT imaging, we were able to reconstruct infection maps in which we could 
segregate disseminated or contained lesions and begin to examine individual lesions for features 
relating to bacterial spread.  Interestingly, we found that only a subset of granulomas 
disseminated to form new, productive (CFU+) granulomas, and that granuloma size early 
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(between 4-5 weeks post infection) correlated with dissemination. When we looked at two 
additional early infection monkeys, we confirmed the early feature of size and found that those 
larger lesions had higher CFU relative to their contained counterparts.  We speculate that there is 
a critical crossroads for granuloma fate in early infection in which early cellular responses, 
bacterial growth, and granuloma size interact to dictate further dissemination or containment 
(Figure 21).  Deciphering the key players that direct either endpoint will be an interesting 
question for future study, particularly as these decisions likely rely on components of the innate 
response given its timing.  Notably, the two early macaques had significant dissemination to the 
thoracic lymph nodes and only minimal early lung spread.  Whether this is indicative of a more 
general phenotype of early spread or an isolated instance found in these two animals is also 
unknown and warrants further study.  Ultimately, this new barcoding scheme has not only 
provided novel depth into disease progression and individual granuloma fate mapping, it has also 
reaffirmed an unappreciated role for early granuloma dynamics in shaping host outcome.   
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Figure 21. Granuloma fate is influenced by a complex and dynamic exchange of host and bacterial features. 
6.2.2 Reinfection in TB: primary infection protects against early secondary infection. 
How an ongoing M. tuberculosis infection influences a subsequent, secondary infection is 
entirely unexplored.  Here we leveraged the macaque model of TB to experimentally assess the 
effect of reinfection on the course of early secondary infection.  Utilizing 18[F]-FDG PET/CT 
imaging and separate library qTags, we differentiated primary and secondary lesions in a 
matched set of macaque experiments where 4 week primary granulomas were directly compared 
against 4 week secondary granulomas.  Excitingly, our data suggested that previous infection is 
protective against reinfection in that it completely protected several animals from developing any 
new secondary granulomas and, of the granulomas that did form, a large majority (>50%) were 
sterile (Figure 12 & Figure 13).  Those with detectable CFU were all significantly diminished 
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versus primary granulomas of the same age (~4 weeks post infection) demonstrating a uniformly 
strong anti-tuberculous response.  Importantly, the level of protection exhibited here is greater 
than that of BCG vaccination191 and any vaccine candidate tested in our macaques to date.  To 
provide better perspective into the bacterial killing seen in reinfection, we compared granuloma 
CFU data from early (5-6 weeks post infection) vaccinated animals that received BCG, an H56 
boost, and a CAF01 adjuvant prior to M. tuberculosis infection (Figure 22) [data courtesy 
Robert DiFazio, unpublished].  The bacterial burden in the secondary granulomas in reinfection 
was considerably lower than the primary granulomas from the vaccinated animals further 
highlighting the magnitude of protection observed in our reinfected animals. (Infectious dose 
was similar for both studies.)  As a result, the immunologic features engendering the protection 
observed in our reinfection studies offer unique potential to identify novel immunological 
biomarkers for better vaccine development. Our initial investigations into some of the protective 
immune responses suggested that the CD3+ T cells from secondary granulomas at 4 weeks post 
infection were poised to produce greater amounts of both pro- and anti-inflammatory cytokines 
than the primary granulomas (Figure 14).  We believe this rapid, balanced cytokine milieu 
contributed to the substantial killing by appropriately pairing macrophage activation and 
bactericidal responses with immune regulatory programs and tissue preserving responses7,30,133 
(modeled in Figure 23).  TH1 responses are likely necessary for appropriate activation of 
macrophages to kill internalized M. tuberculosis32, and most vaccines entering clinical trials have 
relied on induction of IFN-γ+ T cell subsets as a measure of vaccine success6.  However, our 
reinfection data above suggested that multiple cytokines are necessary to achieve protection, at 
least in the context of an early secondary infection.  Intriguingly, IFN-γ was the only cytokine 
not found to be upregulated when we compared primary and secondary granulomas.  It should be 
 93 
noted that this data does not discount the importance of IFN-γ but rather suggests that a broader 
landscape of cytokines is needed to initiate a protective response in TB.  Future studies in 
reinfection are needed to fully understand the immunological basis providing this protection, 
particularly in light of a renewed focus on resident memory T cells192.  In addition, the durability 
of this observed protection as well as the apparent needed for viable M. tuberculosis will have to 
be thoroughly tested.   
 
 
Figure 22. Putting in perspective: bacterial killing in reinfection vs. vaccination.  
(Adapted from Figure 13). CFU of 4 week primary (n=33), 4 week secondary(n=47), and vaccinated, 5-6 week 
primary (n=71) granulomas (****p<0.0001), each symbol is a granuloma.  (Early BCG+H56/CAF01 granuloma 




Figure 23. A balanced cytokine milieu elicits anti-tuberculous immunity and immune regulation. 
 Model of immunity in reinfection.  A primary infection with low dose M. tuberculosis Erdman Library A initiates 
and maintains adaptive immunity including antigen-specific T cells that migrate to granulomas and help promote 
bacterial control and clearance.  While several primary granulomas are sterilized and resolved over 16 weeks, this 
local T cell immunity is rapidly poised to respond to a secondary infection (Library B).  The early production of pro- 
and anti-inflammatory cytokines helps prevent establishment of secondary granulomas and greatly enhances 
bacterial killing whilst diminishing excessive lung inflammation and immunopathology.  
6.2.3 M. tuberculosis alters the lung microbiome. 
The final arm of this dissertation was an initial survey into microbial environment of the lung 
and its relationship with M. tuberculosis infection.  The lung microbiome is arguably among the 
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earliest interactions between host and pathogen, and the role that the microbiota plays in 
influencing host immunity and host response at mucosal sites is becoming increasingly 
apparent129,162,193,194.  By serially sampling the BAL of both infected and uninfected lobes in 
macaques over the course of M. tuberculosis infection, we have provided the first evidence of a 
dynamic interplay between bacterium and host microbiota in the lung.  Specifically, we see an 
increase in microbial diversity in the 4th month post infection in the infected lobe relative to the 
opposite, uninfected lobe that is most likely driven by species of the oropharynx188, as well as a 
concomitant increase in total lung inflammation at the same time point in several macaques 
(Figure 17, Figure 19 & Table 4).  While our data analysis is still preliminary, this shift is 
intriguing as it suggests that the lower airway may undergo increased cross-contamination with 
the upper respiratory tract following infection and inflammation.  The significance of this shift is 
still unclear and requires further study.  In addition to finishing analysis on the remaining 16 
macaques, we are working to associate this lung microbiome alteration with pulmonary 
inflammation in a more detailed, lobe-specific basis.  Such analysis would provide a functional 
relationship to the observed interactions by tying inflammation driven by infection with the 
observed dysbiosis in the lung flora (modeled in Figure 24).  Understanding this cycle of 
inflammation and microbial dysbiosis129 in TB is very exciting as it posits an additional 
component that likely influences the variable responses to host outcome.  Moreover, if precise 
microbe-host-pathogen relationships are identified, it presents an entirely new avenue for 
therapeutic intervention in which particular lung microbes could be used to engage specific 
immune programs and minimize overall inflammation in the hopes of steering more favorable 




Figure 24. Model of M. tuberculosis alteration of the lung microbiome.  
Left panel: normal lung at steady state.  There is a dynamic interplay between the airway and local microbiota that 
maintains an immunological equilibrium.  Right panel: inflammation and dysbiosis in M. tuberculosis infected lung. 
Following successful infection, there is perturbation of the airway concomitant with pulmonary inflammation and 
immune cell recruitment.  These changes alter the local environment allowing for increased colonization with 




6.3 FINAL THOUGHTS  
This dissertation probed early events in three separate and unique contexts, early dissemination 
and disease progression, reinfection, and the lung microbiome.  To address the first two aims, we 
developed and validated a novel tool for use in our macaque model of TB that permitted tracking 
of individual bacilli to determine bacterial fate and granuloma dynamics.  We coupled this 
information with real-time serial [18F]-FGD PET/CT imaging and recreated maps of infection 
that gave us new insight into events that contribute to granuloma outcome.  We observed that 
early features, including granuloma size and bacterial burden, were associated with bacterial 
dissemination.  These two features in tandem with early immune responses are likely key 
components of the initial interactions between host and pathogen that influence host outcome.  
Our new barcoded M. tuberculosis also allowed us to examine how primary infection impacts a 
secondary infection by utilizing library specific qTags that differentiate parental strain.  
Although we are awaiting final confirmation of library identity from our sequencing 
collaborators, our imaging data suggested that we revealed an exciting phenotype of protection in 
which we observed complete protection against new granulomas in several macaques and 
considerable anti-mycobacterial killing in the first weeks in all of the remaining animals.  
Importantly, this protection occurred across the spectrum of host outcomes in primary infection 
in our macaques implicating that significant disease burden in the first infection is not required.  
This is critical as the majority of humans (~90%) dwell within the latent end of the TB spectrum.  
Confirming the apparent requirement for viable M. tuberculosis is equally critical as this would 
be among the first design steps in generating a vaccine (a macaque reinfection study with 
sterilizing drug treatment has just started).  While on the surface the administration of live M. 
tuberculosis might be unpalatable as a vaccine strategy, there are ideas of kill-switch and other 
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severely attenuated strains in the pipeline that offer encouragement for such an approach.  
Finally, and perhaps most readily, this model of macaque reinfection can be used as a robust 
platform to fully dissect the precise immune mechanisms eliciting protection, which can be 
directly translated for use and testing in human TB vaccine settings.  The final segment of this 
thesis set the stage for an interesting set of new studies that will interrogate the interface of the 
local, lung microbiota and M. tuberculosis.  Our first stab has yielded though-provoking 
suggestions on how a trifecta of microbe-host-pathogen interactions may influence infection 
outcome, particularly as a result of inflammation and dysbiosis.  The influence of the 
microbiome on infectious disease and immunity is a very active area of research and by applying 
this fresh perspective to our model of macaque TB, we may uncover new understanding of host 
variability in TB and potentially open new opportunities for early treatment and intervention.   
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8.0  APPENDIX A: VERY LOW DOSES OF MYCOBACTERIUM TUBERCULOSIS 
YIELD DIVERSE HOST OUTCOMES IN COMMON MARMOSETS (CALLITHRIX 
JACCHUS) 
This appendix chapter is adapted from the original publication and represents a side 
project ancillary to my primary thesis in early events:  
Cadena AM, et al. (2016) Very Low Doses of Mycobacterium tuberculosis Yield Diverse 
Host Outcomes in Common Marmosets (Callithrix jacchus). Comp Med 66(5):412-419. 
8.1 INTRODUCTION 
Tuberculosis remains a risk to global public health, with 9.6 million new cases of active 
tuberculosis and 1.5 million deaths in 2014195. Although most humans contain Mycobacterium 
tuberculosis in a clinically asymptomatic infection termed ‘latent tuberculosis,’ a smaller subset 
(approximately 10%) of patients present initially with primary active disease or subsequent 
disease reactivation over the course of their lifetime7. The biologic basis for the disease spectrum 
of M. tuberculosis in humans is unknown and continues to be an active area of research. 
Several animal models have been adapted for experimental M. tuberculosis infection, 
greatly contributing to our understanding of tuberculosis biology196. NHP models of tuberculosis, 
particularly cynomolgus macaques (Macaca fascicularis)49,125 and rhesus macaques (Macaca 
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mulatta)197,198 are recognized as the most faithful animal models in replicating the human 
spectrum of disease in terms of both pathology and infection outcome15,30,125,199. In addition, the 
recently developed common marmoset model of tuberculosis (Callithrix jacchus)200 replicates 
crucial facets of human tuberculosis, including cavitary disease. This model demonstrated 
divergent rates of disease progression after challenge with 3 strains—a Beijing isolate, the less 
virulent strain CDC1551, and M. africanum—and 2 different inocula (250 and 25 CFU). 
Notably, each infection resulted in rapid pulmonary disease presentation and weight loss, and all 
animals died by 75 days after challenge, thus reflecting the inherent susceptibility of common 
marmosets to this infection. 
The influence of M. tuberculosis dose and strain on host outcome has been examined in 
several animal models. For example, BALB/c mice demonstrated a broad range of virulence, 
bacterial load, and pathology after infection with 19 different M. tuberculosis complex strains of 
11 major genotype families113.  These 19 strains were segregated according to their virulence, 
bacterial burden, pathology, and delayed-type hypersensitivity responses as high, intermediate, 
and low responders. Strains that were classified as high responders induced the most pathology, 
greatest bacterial burden and highest mortality and included the isolates Beijing 2 and 3, Africa 
2, and Somalia 2. At the other end of the spectrum, those strains that elicited the least severe 
pathologic scores caused no or minimal mortality after 112 days, yielded the lowest bacterial 
load, and included the isolates H37Rv, Canetti, and Beijing 1113.  A recent review examined the 
virulence and immunogenicity of several genotypic lineages of M. tuberculosis in mice and 
related these findings to observed human epidemiologic data201. Overall, virulence and immune 
response vary extensively within each genotype, with many genotypes having both high- and 
low-virulence variants. Furthermore, rabbits (like mice) demonstrate an influence of dose, strain, 
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and growth phase on tubercle formation and virulence, and M. tuberculosis strain Erdman had 
the greatest virulence in rabbits, requiring the fewest inhaled bacilli to generate visible tubercles 
at 5 weeks202. 
Whether common marmosets have any capacity to control M. tuberculosis infection or 
are universally susceptible to developing active tuberculosis, even with low-dose inocula, has not 
been determined to date. In this study, we aimed to better characterize the disease phenotypes 
and host outcomes of common marmosets after M. tuberculosis infection by challenging animals 
with very low doses (less than 15 CFU) of the Erdman and CDC1551 strains. 
8.2 MATERIALS AND METHODS 
8.2.1 Animals. 
Common marmosets (Callithrix jacchus) were obtained from the Wisconsin National Primate 
Research Center (Madison, WI). Prior to shipment, the animals were tested for Campylobacter, 
Shigella, Salmonella, Giardia, Cryptosporidium, Entamoeba, and Balantidium. On arrival at the 
University of Pittsburgh, the marmosets were screened for M. tuberculosis infection and other 
comorbidities during a month-long quarantine. More specifically, each macaque underwent 
complete baseline blood and biochemical analyses, 2 tape tests to screen for pinworms, and 
Giardia ELISA with 2 pooled fecal sets. All marmosets were housed and maintained according 
to the practices and standards detailed in the Animal Welfare Act and the Guide for the Care and 
Use of Laboratory Animals within a biosafety level 3 facility. These NHP were housed in a 4 × 4 
macaque cage system, with the internal dividers removed to allow for open access and 
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opportunities for climbing to the top and bottom of the cage. A nest box was included in the 
upper part of the cage, and the animals were fed a specialized marmoset diet (as advised by Dr 
Saverio Capuano, Wisconsin Primate Center). In some cases, infected animals were cohoused 
with naïve cagemates for a separate transmission study. The IACUC at the University of 
Pittsburgh approved all protocols and experiments. 
8.2.2 Infection and necropsy. 
Common marmosets were infected with either the virulent Erdman strain of M. tuberculosis or 
CDC1551 at doses of 1 to 12 CFU, as determined by plating the inoculum. One animal in the 
Erdman cohort was infected by aerosol, and the remaining marmosets were infected through 
bronchoscopic instillation, as previously described125. In brief, a disinfected bronchoscope was 
placed into the desired bronchus and 0.2 mL of sterile saline containing the appropriate infection 
inoculum was instilled. For the marmoset infected by aerosol, an infection inoculum was 
administered through a 10-min exposure to aerosolized bacilli created by a 3-jet Collison 
nebulizer (BGI, Waltham, MA) controlled by the AeroMP bioaerosol exposure system (Biaera 
Technologies, Hagerstown, MD) in a head-only exposure chamber (CH Technologies, 
Westwood, NJ) within a class III biologic safety cabinet (Baker, Sanford, ME). After infection, 
all marmosets were clinically monitored for signs of infection according to previously published 
methods49,125, and 18F-fluorodeoxyglucose positron-emission tomography–CT (PET–CT) scans 
were performed monthly, as previously described39,109,200. Marmosets were euthanized when they 
lost more than 20% of their preinfection body weight or when they exhibited substantial clinical 
signs of disease (for example, lethargy and anorexia). At necropsy, a gross pathology score for 
each marmoset was determined according to our published scoring system49, which evaluates 
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tuberculosis-specific disease in all lung lobes, thoracic lymph nodes, and extrapulmonary sites. 
Overall bacterial burden scores and CFU counts for individual granulomas, regions of complex 
pathology (for example, tuberculosis pneumonia), and thoracic lymph nodes were quantified and 
calculated as previously described36,49. Briefly, multiple individual tissue samples in each 
marmoset were identified by using PET–CT imaging as a guide, excised, and plated at necropsy, 
and bacterial colonies were counted 21 d after necropsy. The CFU score for each animal was 
determined by summation of each tissue’s log-transformation of bacterial burden, thus providing 
a relative comparator for all marmosets. In comparison, the total CFU count was the sum of the 
actual number of bacilli in all samples taken from the animal, and thus provided a more accurate 
representation of the bacterial burden. 
8.3 RESULTS 
8.3.1 Host outcome after M. tuberculosis infection in marmosets 
To determine the clinical progression and disease pathology of very low-dose infection, 9 
marmosets were challenged with 2 different strains of M. tuberculosis at doses of 1 to 12 CFU 
(Table 5). Inocula were determined by plating at the time of challenge. All but one of the 
marmosets in this study were infected by direct instillation of bacteria into the airways by using a 
bronchoscope. The marmoset that received 12 CFU of the Erdman strain (animal no. 3012) was 
infected through aerosol dispersion. All marmosets infected with the Erdman strain (dose range, 
1 to 12 CFU, with most animals infected with 2 CFU) presented with rapidly progressing disease 
regardless of dose. Clinically, all of these marmosets exhibited physical signs of illness, 
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including inactivity, reclusiveness, and diminished appetite. The animals exhibited precipitous 
weight loss after infection and arrived at the weight-loss threshold of 20% by 45 days after 
infection (median, 39 days), requiring euthanasia (Figure 25). Coughing was observed in a 
subset of animals (marmosets 13210, 13310, 13410, 13610, 13710, and 3412). At necropsy, all 
animals infected with strain Erdman had gross pathology scores that exceeded 30 (median score, 
41; Table 5). 
 
Table 5. Survival, disease presentation, and bacterial burden and dissemination after infection of common 
marmosets with very low doses of M. tuberculosis infection. 
aCFU = Colony forming units 
 
By contrast, the 2 marmosets challenged with strain CDC1551 (dose, 1 or 7 CFU) had 
divergent outcomes associated with dose but demonstrated reduced overall disease compared 
with that of marmosets infected with strain Erdman. The marmoset that received 7 CFU of the  
CDC1551 strain (animal no. 3913) had mild to moderate disease progression and steady 
weight loss and survived to 89 days (Table 5 and Figure 26). Surprisingly, the marmoset that 
received 1 cfu of CDC1551 (animal no. 3713) had mild disease progression, with a sustained 
period of weight loss in this animal beginning on day 76 that was not accompanied by any other 











13210 Mtb Erdman 
 
2 39 49 142 100 
13310 2 35 56 164 100 
13410 2 37 41 158 100 
13610 2 38 31 123 100 
13710 2 40 33 137 95.2 
3012 12 32 53 144 100 
3412 1 43 33 107 100 
       3713 CDC1551 1 307 25 26 32 
3913 7 89 66 53 100 
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clinical signs of disease. By day 174, this marmoset was regaining weight and returned to its 
initial weight by day 282 (Figure 25). This marmoset was euthanized after the conclusion of the 
study on day 307; euthanasia was not due to weight loss or clinical morbidity.  
The marmoset inoculated with 7 CFU had a gross pathology score of 66, whereas the 
marmoset inoculated with 1 CFU had a score of 25 (Table 5).  
 
 
Figure 25. Weight loss after infection with very low doses of M. tuberculosis varied according to strain and 
dose. 
All animals except one had sustained weight loss that prompted euthanasia by 90 days. The marmoset infected with 
1 CFU of CDC1551 (animal no. 3713) had a period of weight loss by recovered its preinfection body weight by day 
282. This animal was euthanized at 307 days after infection due to the conclusion of the study.  
8.3.2 In vivo PET–CT imaging. 
To compare in vivo disease progression between strains and doses, all marmosets were followed 
by using serial PET–CT imaging39,109; we here present 2 representative animals from each cohort 
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for comparison. For strain Erdman, 2 marmosets (nos. 3012 and 3412) were imaged and 
compared with 2 animals infected with CDC1551 (nos. 3913 and 3713). Both sets of animals 
represented the highest and lowest dose administered for each strain (Table 5). In agreement 
with clinical and weight observations, these marmosets had differing rates of disease 
progression, as demonstrated by 18F-fluorodeoxyglucose uptake. Relative to their baseline scans, 
both Erdman-infected marmosets had activity indicative of pulmonary and lymphatic disease on 
their 4 week postinfection PET–CT scans (Figure 26, yellow arrows), whereas the 2 animals 
challenged with CDC1551 had normal scans without disease, thus reflecting the slower 
progression associated with this strain. The prenecropsy scan for each animal was obtained just a 
few days prior to euthanasia. Given the rapid loss of body weight that necessitated early 
euthanasia in the 2 Erdman-infected marmosets, the 4 week scans served as their prenecropsy 
scans. By contrast, the disease in the CDC1551-infected marmosets progressed more slowly 
(prenecropsy scans at weeks 12 and 44). In particular, marmoset 3913 had significant disease in 
the right lower lung lobe and thoracic lymph nodes (Figure 26, yellow arrows), and marmoset 
3713 (dose, 1 CFU of CDC1551) had very little 18F-fluorodeoxyglucose uptake during his 
prenecropsy scan at 300 days after infection. 
8.3.3 Overall bacterial burden and extent of dissemination. 
Comparisons of bacterial burden (CFU scores)49 and the number of bacteria per tissue sample 
(granuloma, lymph node, tuberculosis pneumonia)36 revealed strain- and dose-dependent 




Figure 26. Serial PET/CT imaging of infected marmosets revealed variable disease progression that was 
dependent on dose. 
These images are representative PET/CT coronal cross-sections from marmosets infected with very low doses of M. 
tuberculosis; 18F-flurodeoxyglucose was used as a probe for inflammation. Left panel: 2 marmosets infected with 
the Erdman strain (doses, 12 and 1 CFU) were followed over the course of infection. For both animals, their 4 week 
scans served as their prenecropsy scans, in light of their rapid disease progression and clinical decline. Right panel: 
2 marmosets infected with CDC1551 (doses, 7 and 1 CFU) were followed throughout infection. For all animals, the 
date of each prenecropsy scan (in weeks) is labeled at the lower left. Yellow arrows denote diseased areas of lung 
and thoracic lymph nodes, whereas the white arrow highlights noninflammatory uptake in the heart.  
 
 110 
All of the Erdman-infected marmosets (including the one that received a dose of 1 CFU) had 
CFU scores above 100 (median, 142) and more than 95% of the tissues cultured were positive 
for M. tuberculosis (Table 5), indicative of prominent and widespread disease. By contrast, the 2 
marmosets challenged with 7 and 1 CFU of CDC1551 had CFU scores of 53 and 26, 
respectively, supporting the finding that bacterial burden is related to dose for this strain (Figure 
27A). The inoculation dose of 7 CFU of CDC1551 resulted in 100% of tissues that were positive 
for tubercular bacilli, whereas the infection due to the 1-cfu dose was contained to a much 
greater extent, with only 32% of tissues positive for bacteria (Table 5). Two marmosets from the 
Erdman group (no. 3012, inoculated with 12 CFU, and no. 3412, which received 1 CFU) were 
selected for more precise comparison of tissue burden with the 2 animals infected with CDC1551 
(marmosets 3913 and 3713). Comparisons of each animal’s cumulative bacterial burden (total 
CFU counts among all lung and lymph node samples) revealed that 3 of the marmosets had 
cumulative burdens that exceeded 5 × 106 CFU, with little difference between the lung and 
lymph-node compartments (Figure 27B). In contrast, the total bacterial load in the marmoset 
infected with 1 CFU of CDC1551 (no. 3713) was nearly 100-fold lower than that in the other 3 
(Figure 27B), with the vast majority of the burden contributed by infected thoracic lymph nodes 
(Figure 27C). Assessing each tissue separately revealed that the median lung or lymph node 
bacterial burden was higher in the 2 animals that received the higher dose within each strain 
(Figure 27C). Lymph nodes had the greatest variability across the different tissues, and the 
highest burdens occurred in regions of lung tuberculosis pneumonia. Most notably, the tissue 
bacterial burden in the marmoset that received 1 CFU of CDC1551 ranged from primarily sterile 




Figure 27. Very low dose infection with CDC1551 results in diminished bacterial burden. 
(A) Comparisons of CFU scores for all 7 marmosets reveal the decreased scores for the 2 animals that received 
CDC1551. (B) Total CFU counts (the sum of all bacilli from every plated sample) and (C) the number of cfu per 
tissue sample from a subset of marmosets reveal the reduced bacterial loads in the 2 marmosets infected with 
CDC1551. In the marmoset infected with 1 CFU of CDC1551 (animal no. 3713), the total bacterial burden was 
approximately 2 logs lower than that in any other animal, and there were fewer bacilli in individual tissues, with a 
majority of samples being sterile. 
 
8.3.4 Gross and histologic disease pathology after challenge with very low doses of M. 
tuberculosis. 
Comparison of gross pathology at necropsy (Figure 28) revealed marked differences in the 
magnitude and extent of disease progression. For example, marmoset 3412, which was infected 
with 1 CFU of the Erdman strain, demonstrated pulmonary disease that was grossly limited to 
the left lower lung (Figure 28A), with concomitant enlargement and effacement of the left 
thoracic lymph nodes (Figure 28B). The left lower lobe showed extensive tuberculous 
pneumonia, with a central focal area of severe necrotizing consolidation (2 cm); the lobe 
completely lacked any normal, aerated lung parenchyma. Gross examination of the spleen and 
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liver revealed enlargement of both organs, with numerous (20 or more) granulomas (diameter, 
pinpoint to 1 mm or greater) throughout (Figure 28C). 
By contrast, gross examination of tissues from the marmoset infected with 1 CFU of 
CDC1551 (no. 3713) revealed 2 relatively well-circumscribed lesions in the left (lesion diameter, 
1.5 mm) and right (10 mm) lower lobes (Figure 28D); there were 4 additional discrete lesions 
(diameter, 2 mm or less) in the right lower lobe. The inferior and superior pretracheal lymph 
nodes were both enlarged, with significant effacement in the superior node (Figure 28E). The 
liver (Figure 28F) and spleen had no readily identifiable gross lesions. The liver was markedly 
enlarged, extending several centimeters below the costal region, and had an accentuated lobular 
appearance, with several large, irregular, superficial regions of parenchymal pallor. This 
discoloration was likely due to differential blood settling, euthanasia-solution–induced 
hepatocellular artifact, or glycogenation; there was no gross indication of tuberculosis throughout 
this organ. 
Histopathology of lung, thoracic lymph nodes, spleen, and liver largely confirmed the 
findings at necropsy. For the marmoset challenged with 1 CFU of the Erdman strain (animal 
3412), the region of tuberculosis pneumonia in the left lower lobe consisted of extremely 
neutrophil-rich inflammatory infiltrate, extending from alveolus to alveolus. Centrally, there was 
a large area of coagulative necrosis with near total effacement of all recognizable tissue 
architecture. There was minimal evidence of the formation of architecturally organized 
granuloma structures per se within the entirety of the large necrotizing region (Figure 29A). The 
left cranial hilar lymph node displayed extensive nodal effacement, with regions of necrotizing 
and nonnecrotizing inflammation with poor structural organization (Figure 29B). Examination 
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of the spleen (Figure 29C) and liver (Figure 29D) revealed multiple regions of caseous and 
nonnecrotizing granulomas, indicative of widespread disseminated disease. 
 
 
Figure 28. Gross pathology after infection with very low doses of CDC1551 was reduced relative to that after 
Erdman. 
Representative gross pathology from 2 marmosets infected with 1 CFU of the Erdman strain (top row) and 1 CFU of 
CDC1551 (bottom row). These images show the major disease-associated differences between the 2 animals. (A) 
Left lower lobe of lung with a central consolidation. (B) Enlarged and effaced left cranial hilar and left mainstem 
bronchial nodes, with mildly swollen central carinal lymph nodes. (C) Enlarged spleen and liver, with many 
disseminated pinpoint granulomas. (D) Granuloma in right lower lobe of lung. (E) Enlarged superior pretrachael 





In the marmoset challenged with 1 CFU of CDC1551 (animal 3713), the left lower lung 
lobe contained a single, caseous granuloma that was well circumscribed and had a prominent 
lymphocytic cuff (Figure 29D). In contrast to lung, the superior pretracheal lymph node had 
prominent coalescing and effacing caseous granulomas, with evidence of early collagen fibril 
formation within the necrotic matrix (Figure 29E). Despite the lack of gross disease at necropsy, 
this marmoset had microscopic evidence of splenic tuberculosis, with multiple, small minimally 
necrotizing granulomas (Figure 29F). In addition, sections of liver exhibited several focal areas 
containing caseous granulomas and small, nonnecrotizing sinusoidal granulomas (Figure 29F). 
Overall, the gross and microscopy pathology mirrored the clinical differences in these 2 
marmosets and reiterate the distinction between the 2 strains, even at very low doses. Similar 
extensive gross and microscopic disease was present in all marmosets infected with the Erdman 
strain as well as in the animal infected with 7 CFU of strain CDC1551. Importantly, despite the 
marked difference in the general histologic appearance between the 2 CDC1551-infected animals 
and the more immunologically contained response in the marmoset challenged with 1 CFU, this 
marmoset had numerous microscopic findings that suggested that the disease was entering a 
more widely disseminating stage. The presence of numerous small nonnecrotizing granulomas 
and epithelioid cell aggregates within thoracic lymph nodes as well as the microscopic 
granulomas in the hepatic and splenic parenchyma indicated the onset of more fulminant and 




Figure 29. Histopathology after infection with very low doses of the Erdman and CDC1551 strains. 
Representative histopathology from the 2 marmosets shown in Figure 4, which were infected with 1 CFU of the 
Erdman strain (top row) and 1 CFU of CDC1551 (bottom row). These images illustrate the differences between the 
2 animals, particularly in the organization and structure of the lung granulomas. (A) Tuberculosis pneumonia with a 
large area of necrosis in the left lower lung lobe; magnification, 1.25×. (B) Left cranial hilar lymph node with areas 
of necrotizing and nonnecrotizing granulomatous inflammation; magnification, 4×. (C) Spleen with disseminating 
necrotizing and nonnecrotizing foci; magnification, 4×. (D) Liver with caseous granuloma; magnification, 10×. (E) 
Circumscribed caseous granuloma with a well-defined lymphocytic cuff in the left lower lung lobe; magnification, 
4×. (F) Superior pretracheal lymph node with coalescing and effacing caseous granulomas; magnification, 4×. (G) 
Spleen with multiple areas of minimally necrotizing granulomas dispersed throughout the parenchyma; 
magnification, 4×. (H) Liver with several, small sinusoidal nonnecrotizing granulomas; magnification, 10×. 




Here we report the diverse disease progression and host outcome patterns that occurred after the 
infection of common marmosets with very low doses (1 to 12 CFU) of 2 strains of M. 
tuberculosis. The susceptibility of marmosets to the Erdman strain was unrelated to dose or 
route. However, the inoculation dose may be an important determinant of outcome after 
challenge with the less virulent CDC1551 strain. All of the marmosets challenged with low doses 
of strain Erdman presented with fulminant, disseminating active tuberculosis, had a median 
survival time of 39 days, and had evidence of invasive necrotizing alveolitis and tuberculosis 
pneumonia, with little evidence of well-circumscribed granulomas. In contrast, infection with 
CDC1551 promoted an more slowly progressing infection overall; the marmoset that received 7 
CFU survived to 89 days, and the animal given 1 CFU survived more than 300 days. To our 
knowledge, this is the first reported instance of apparent recovery, stabilization, and survival 
beyond 300 days of a marmoset infected with a strain of M. tuberculosis. 
Our initial findings recapitulated those reported by our colleagues, who also described 
differential disease progression between several strains within the M. tuberculosis complex200. 
This previous study compared CDC1551, M. africanum N0091, and a Beijing K04 isolate at 
doses of 25 and 250 cfu; all 3 strains at both doses produced fulminant disease and prompted 
euthanasia by 80 d after infection due to weight loss200. The rapid disease progression, high 
bacterial burden, and invasive necrotizing pathology associated with the Beijing K04 isolate is 
very similar to the disease evolution, bacterial load, and disease presentation in our marmosets 
that were infected with the virulent Erdman strain. The median survival time in the previous 
study was 37 days200, similar to the 39 days for Erdman-infected marmosets in the current study. 
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Moreover, the higher dose of the K04 isolate was the only case for which the rate of weight loss 
was significantly increased. Likewise, among the Erdman-infected marmosets in our study, the 
animal that received 12 cfu had the most rapid weight decline and was euthanized 32 days after 
infection. In contrast, infection with CDC1551 resulted in the slowest disease progression among 
the 3 strains evaluated previously and yielded a median survival time of 59 days200. Notably, half 
of the marmosets infected with the CDC1551 strain previously developed cavitary lesions, a 
particular manifestation of human tuberculosis that is associated with erosion of lung 
parenchyma into the airway, facilitating bacterial transmission203. In agreement with these 
findings, our marmoset that received 7 CFU of CDC1551 (no. 3913) demonstrated several sites 
of cavitation. A separate study performed by these collaborators200,204 followed marmosets 
infected with various low aerosol doses of CDC1551 for weight loss in infected animals prior to 
drug treatment at 7 weeks. Little to no weight loss was seen in the animals exposed to 1 to 2 
CFU, whereas infection with higher doses significantly increased weight loss percentage (data 
not shown) suggesting that the route of infection was not directly responsible for the difference 
observed in the marmoset infected with 1 CFU of CDC1551 presented here. 
Extending the published findings, we present data supportive of long-term control of 
infection in a single marmoset. Infection with approximately 1 CFU of CDC 1551 presented as 2 
primary lesions, one in each of the lower lung lobes, as determined by PET–CT imaging39,109 
(Figure 2). Except for a period of transient weight loss beginning at day 76 after infection, this 
marmoset showed no other sign of clinical morbidity. Close observation by PET–CT imaging 
revealed that the lesion in the right lower lobe gradually increased in tracer uptake, whereas the 
signal in the lesion in the opposite lobe gradually decreased, suggesting at least partial 
immunologic control and disease resolution. This apparent discrepancy between the 2 individual 
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lesions is characteristic of the independent nature of granulomas even within the same NHP 
host36,39. These results were confirmed at necropsy, in that the lesion in the left lower lobe was 
sterile (that is, yielded no organisms by plating), whereas the lesion in the right lower lobe had 
approximately 2.6 × 103 bacteria. However, the microscopic pathology in the nodal lymph nodes 
and the presence of microscopic granulomas in the liver and spleen suggest that the infection 
may have been entering a more invasive stage, albeit at a slower rate than reported for all other 
marmosets to date. The histologic characteristics of the 2 lung lesions from this animal were 
distinct from the granulomas excised from the marmoset infected with 7 CFU of the same strain 
and from any of marmosets challenged with the Erdman strain. The left lower lobe lesion was an 
archetypical caseous granuloma with a well-circumscribed lymphocytic cuff, whereas the right 
lower lobe lesion had areas of tuberculosis pneumonia and nonnecrotizing granulomas. All of the 
Erdman-infected animals had a predominance of invasive, neutrophil-rich granulomatous 
alveolitis in their pulmonary sites that exhibited occasional organization and circumcision but did 
not form traditional defined granulomatous structures. Overall, the recovery of body weight and 
the lack of clinical manifestations coupled with the postmortem observations of decreased total 
cfu counts, diminished bacterial dissemination, and less extensive gross pathology suggest that 
the marmoset’s greater capacity to limit disease progression was likely due to the reduced 
virulence of CDC1551 and the very low infection dose. 
The primary limitation of our study is that the stable but chronic infection phenotype has 
only been observed in the single marmoset described.  However, we found a strong relationship 
between the infectious dose of CDC1551 and weight loss in marmosets. Further infections with 1 
to 3 CFU of CDC1551 are warranted in this small animal model to better define the mechanisms 
of control of low-dose infection. If this NHP species does exhibit relative resistance to M. 
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tuberculosis in a persistent manner, it would broaden their applicability as a small animal model 
of tuberculosis to include chronic infection studies yet retain their inherent benefits as a NHP 
model that offers decreased cost, small size205, dizygotic twinning206, pliability for drug 
studies204, and the ability to replicate aspects of human disease200,205. In addition, marmosets 
might be developed as a model for vaccine-induced protection against tuberculosis. 
In conclusion, optimizing the common marmoset (C. jacchus) model of M. tuberculosis 
infection requires identification of the range of host outcomes for this NHP species. In the 
current study, we noted variable disease progression in marmosets challenged with very low 
doses (1 to 12 CFU) of 2 strains of M. tuberculosis. Both the dose and strain of M. tuberculosis 
influenced the outcomes after challenge. Very low-dose challenge with the virulent Erdman 
strain did not ameliorate the rate of disease progression, because all of these marmosets (even 
those infected with 1 to 2 CFU) presented with rapidly disseminating active disease, resulting in 
clinical decline that prompted euthanasia by 43 days after inoculation. Infection with the less 
virulent CDC1551 strain resulted in delayed disease progression that was somewhat dependent 
on the inoculation dose. One of the most striking findings was that challenge with approximately 
1 CFU of CDC1551 produced one case in which a marmoset effectively controlled the M. 
tuberculosis infection in a subclinical state for more than 300 days. At necropsy, this marmoset 
had reduced bacterial burden in its involved lymph nodes and lungs, reduced tissue 
dissemination, less overt gross pathology, and mildly progressing histology. These findings are 
in stark contrast to all previously reported M. tuberculosis infections of common marmosets, thus 
potentially extending this small-animal model beyond studies of acute infection while 
maintaining the clinical spectrum observed in the human disease. 
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9.0  APPENDIX B: SUPPLEMENTARY TABLES & FIGURES 




Figure 30. Barcode counting.  
A. Pictorial example of BARTI thresholding ‘real’ barcodes from ‘noise’ arising from sequencing artifact. Unique 
barcodes from 25 picked M. smegmatis colonies are rank-ordered by number of molecular counters. The inflection 
point can be visually described as the largest drop-off between two barcode sequences and is mathematically 
described and found in the methods section (Section 3.4.6).  B. BARTI has good accord between expected and 




Figure 31. Distance between lesions.   
Euclidean distance between each lung granuloma to every other lesion in that animal. Contained lesions in blue, 











Figure 32. Frequency of cytokine producing T cells for IFN- (A), IL-2 (B), IL-6 (C), IL-10 (D), IL-17A (F), 
and TNF show minor differences between contained and disseminated lesions.  
Each symbol is a granuloma.  Analyzed contained (n=7) and disseminated (n=12) lesions had a minimum of 30 
CD3+ T cells after processing and gating in FlowJo (ver. 9.9.5) for analysis (*p=0.0.283, **p=0.0098).  Statistics 














Figure 33. Size is not associated with granuloma bacterial burden.  
There is a very weak correlation between granuloma size, as measured by PET/CT at 4-5 weeks post infection and 
CFU in granulomas necropsied at both 15-19 weeks post infection (A) (r2=0.140, p=0.001, n=71) and 5-6 weeks (B) 
(r2=0.066, p=0.0391) post infection.  Linear regressions performed in Prism 6. 
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